113. 筋ジストロフィー Disease details / Clinical trials / Drug dev / DR info

12 MG/KG GSK2402968
   GlaxoSmithKline
      2010   Phase 1   NCT01128855   France;United States
2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49D RNA
   Antisense Therapeutics Limited
      2023   Phase 2   EUCTR2022-003065-38-BG   Australia;Bulgaria;Serbia;Türkiye;United Kingdom
2011-2012 seasonal FLU vaccine intramuscular
   Children's Hospital Medical Center, Cincinnati
      2011   Phase 4   NCT01422200   United States
2011-2012 seasonal FLU vaccine subcutaneous
   Children's Hospital Medical Center, Cincinnati
      2011   Phase 4   NCT01422200   United States
29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00
   Universitätsklinik Freiburg
      2005   Phase 2;Phase 3   EUCTR2005-000663-26-AT   Austria
3 MG/KG GSK2402968
   GlaxoSmithKline
      2010   Phase 1   NCT01128855   France;United States
30 seconds SIT TO stand test
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
4-benzyl-2-naphthalen-1-YL-1,2,4- thiadiazolidine-3,5-dione
   AMO Pharma Ltd.
      2016   Phase 2   EUCTR2016-000067-16-GB   United Kingdom
4-benzyl-2-naphthalen-1-YL-1,2,4-thiadiazolidine-3,5-dione
   AMO Pharma Ltd
      2018   Phase 2;Phase 3   EUCTR2016-004623-23-GB   Canada;United Kingdom;United States
5-(ethylsulfonyl)-2-(naphthalen-2-YL)benzo[D]oxazole
   Summit Corporation plc
      2013   Phase 1   EUCTR2013-002115-99-GB   United Kingdom
6 MG/KG GSK2402968
   GlaxoSmithKline
      2010   Phase 1   NCT01128855   France;United States
9 MG/KG GSK2402968
   GlaxoSmithKline
      2010   Phase 1   NCT01128855   France;United States
AAV1-gamma-sarcoglycan vector injection
   Genethon
      2006   Phase 1   NCT01344798   France
AB-1003 dose level 1
   Asklepios Biopharmaceutical, Inc.
      2023   Phase 1/Phase 2   NCT05230459   United States
AB-1003 dose level 2
   Asklepios Biopharmaceutical, Inc.
      2023   Phase 1/Phase 2   NCT05230459   United States
ACE-031 0.5 MG/KG Q4WK
   Acceleron Pharma, Inc.
      2010   Phase 2   NCT01099761   Canada
ACE-031 1.0 MG/KG Q2WK
   Acceleron Pharma, Inc.
      2010   Phase 2   NCT01099761   Canada
ACE-083
   Acceleron Pharma Inc.
      2019   Phase 2   EUCTR2019-000305-79-ES   Canada;Spain;United States
      2018   Phase 2   EUCTR2016-003257-15-ES   Canada;Spain;United States
   Acceleron Pharma, Inc.
      2019   Phase 2   NCT03943290   Canada;Spain;United States
      2016   Phase 2   NCT02927080   Canada;Spain;United States
Activity monitor
   Pfizer
      2020   -   NCT04254172   United States
Actonel once A week 5MG film coated tablets
   The Central Remedial Clinic and The Children's University Hospital
      2010   Phase 2   EUCTR2009-017649-67-IE   Ireland
Adeno-associated viral vector serotype 8 containing THE human MD1 gene
   Genethon
      2020   Phase 1;Phase 2;Phase 3   EUCTR2020-002093-27-FR   France;Israel;United Kingdom;United States
Adeno-associated viral vector serotype 9 containing THE human MINI-dystrophin gene
   Pfizer Inc.
      2022   Phase 3   EUCTR2019-002921-31-DE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-002921-31-FR   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-002921-31-BE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002921-31-GB   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
Adeno-associated virus serotype 9 carrying THE human fukutin-related protein and target sequence OF THE MIR-208A
   Atamyo Therapeutics
      2022   Phase 1;Phase 2   EUCTR2021-004276-33-FR   Canada;Denmark;France;Germany;Norway;Sweden;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2021-004276-33-DK   Canada;Denmark;France;Germany;Norway;Sweden;United Kingdom;United States
Adeno-associated virus serotype RH74 containing THE human delandistrogene moxeparvovec dystrophin gene
   Sarepta Therapeutics, Inc.
      2022   Phase 3   EUCTR2019-003374-91-DE   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003374-91-BE   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
Adeno-associated virus serotype RH74 containing THE human micro- dystrophin gene
   Sarepta Therapeutics, Inc.
      2023   Phase 3   EUCTR2020-002372-13-FR   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
Adeno-associated virus serotype RH74 containing THE human micro-dystrophin gene
   Sarepta Therapeutics, Inc
      2023   Phase 1   EUCTR2022-003407-15-ES   Spain
   Sarepta Therapeutics, Inc.
      2023   Phase 3   EUCTR2020-002372-13-BE   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002372-13-SE   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003374-91-FR   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003374-91-ES   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
Agamree
   Santhera Pharmaceuticals (Schweiz) AG
      -   Phase 2   EUCTR2025-000201-16-Outside-EU/EEA   Canada
Albuterol
   Ohio State University
      1998   -   NCT00004685   -
Allogeneic cardiosphere-derived cells
   Capricor Inc.
      2018   Phase 2   NCT06304064   United States
      2016   Phase 2   NCT02485938   United States
Amino acid intake
   McGill University
      2025   -   NCT06785428   Canada
Amondys 45
   Kevin Flanigan
      2020   Phase 2   NCT04179409   United States
ANTI-myostati
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
ANTI-myostatin adnectin
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001654-18-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001654-18-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-SE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-NL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
AOC 1001
   Avidity Biosciences, Inc.
      2024   Phase 3   NCT06411288   Canada;Denmark;France;Germany;Ireland;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   NCT05479981   United States
      2021   Phase 1/Phase 2   NCT05027269   United States
AOC 1020
   Avidity Biosciences, Inc.
      2024   Phase 2   NCT06547216   Canada;United Kingdom;United States
      2023   Phase 1/Phase 2   NCT05747924   Canada;Netherlands;United Kingdom;United States
AOC 1044
   Avidity Biosciences, Inc.
      2024   Phase 2   NCT06244082   United States
      2022   Phase 1/Phase 2   NCT05670730   United States
ARO-DM1 FOR injection
   Arrowhead Pharmaceuticals
      2024   Phase 1/Phase 2   NCT06138743   Australia;New Zealand;Taiwan;Thailand
ARO-DUX4 FOR injection
   Arrowhead Pharmaceuticals
      2024   Phase 1/Phase 2   NCT06131983   Australia;New Zealand;Thailand
Aspirin
   Kobe University Graduate School of Medicine
      2012   Phase 1,2   JPRN-UMIN000009307   Japan
   National Hospital Organization Toneyama National Hospital
      2014   -   JPRN-UMIN000016092   Japan
ATA-200
   Atamyo Therapeutics
      2025   Phase 1/Phase 2   NCT05973630   France;Italy;United States
Ataluren
   PTC THERAPEUTICS, INC.
      2012   Phase 3   EUCTR2011-004853-18-IT   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-007648-32-IT   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
   PTC Therapeutics
      2021   Phase 2   NCT04336826   United States
      2019   Phase 2   NCT03796637   United States
      2018   Phase 2   NCT03648827   United States
      2017   Phase 3   NCT03179631   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Puerto Rico;Russian Federation;Sri Lanka;Taiwan;Thailand;Turkey;United States
      2016   Phase 2   NCT02819557   United States
      2014   Phase 3   NCT02090959   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   NCT01826487   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2012   Phase 3   NCT01557400   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2010   Phase 3   NCT01247207   Canada;United States
      2010   Phase 2   NCT01009294   United Kingdom;United States
      2009   Phase 2   NCT00847379   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States
      2008   Phase 2   NCT00759876   United States
      2008   Phase 2   NCT00592553   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States
   PTC Therapeutics (Medpace Japan K.K.. ; In-Country Caretaker for Clinical trials).
      2018   Phase 3   JPRN-jRCT2080224563   Asia except Japan;Europe;Japan;North America;Oceania;South America
   PTC Therapeutics, Inc
      2014   -   EUCTR2012-004527-20-PL   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004527-20-SE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   -   EUCTR2012-004527-20-IT   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004527-20-GB   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   -   EUCTR2012-004527-20-ES   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004527-20-DE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004527-20-CZ   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004527-20-BE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004853-18-SE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2011-004853-18-FR   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2011-004853-18-ES   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2011-004853-18-BE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2012-004527-20-FR   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   PTC Therapeutics, Inc.
      2018   Phase 3   EUCTR2017-001223-49-BG   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2013-005489-20-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005489-20-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005489-20-BG   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-SE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004853-18-GB   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2011-004853-18-DE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-007648-32-SE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-007648-32-GB   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-007648-32-FR   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-007648-32-ES   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-007648-32-DE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-007648-32-BE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2007-005478-29-GB   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-005478-29-SE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-005478-29-DE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-005478-29-BE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      -   Phase 2   EUCTR2020-000980-21-Outside-EU/EEA   United States
      -   Phase 3   EUCTR2017-001223-49-PL   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States
   Penematsa Vinay
      2021   Phase 3   JPRN-jRCT2041200087   China;Japan
Ataluren 1000 MG
   PTC Therapeutics Inc
      2010   -   EUCTR2009-013169-24-GB   United Kingdom
Ataluren 125 MG
   PTC Therapeutics Inc
      2010   -   EUCTR2009-013169-24-GB   United Kingdom
Ataluren 250 MG
   PTC Therapeutics Inc
      2010   -   EUCTR2009-013169-24-GB   United Kingdom
ATL 1102
   Antisense Therapeutics Limited
      2023   Phase 2   EUCTR2022-003065-38-BG   Australia;Bulgaria;Serbia;Türkiye;United Kingdom
ATL1102
   Antisense Therapeutics Limited
      2023   Phase 2   EUCTR2022-003065-38-BG   Australia;Bulgaria;Serbia;Türkiye;United Kingdom
ATL1102 25MG
   Percheron Therapeutics
      2023   Phase 2   NCT05938023   Australia;Bulgaria;Serbia;Turkey;United Kingdom
ATL1102 50MG
   Percheron Therapeutics
      2023   Phase 2   NCT05938023   Australia;Bulgaria;Serbia;Turkey;United Kingdom
ATX-01
   ARTHEx Biotech S.L.
      2024   Phase 1/Phase 2   NCT06300307   Canada;France;Italy;Spain;United Kingdom;United States
ATYR1940
   ATYR PHARMA, INC.
      -   Phase 1;Phase 2   EUCTR2016-000624-25-IT   Denmark;Italy
      -   Phase 1;Phase 2   EUCTR2014-003346-27-IT   France;Italy;United States
   aTyr Pharma, Inc.
      2016   Phase 1/Phase 2   NCT02836418   Denmark;Italy;United States
      2016   Phase 1/Phase 2   NCT02603562   France;Italy;United States
      2016   Phase 1;Phase 2   EUCTR2016-000624-25-DK   Denmark;Italy;United States
      2015   Phase 1/Phase 2   NCT02579239   Denmark;France;Italy;United States
      2015   Phase 1/Phase 2   NCT02531217   Italy;Netherlands;United States
      2015   Phase 1;Phase 2   EUCTR2015-001912-36-NL   Italy;Netherlands;United States
      2015   Phase 1;Phase 2   EUCTR2015-001910-88-DK   Denmark;France;Italy;United States
      2014   Phase 1/Phase 2   NCT02239224   France;Italy;Netherlands;United States
      2014   Phase 1;Phase 2   EUCTR2014-001753-17-NL   France;Italy;Netherlands;United States
      2014   Phase 1;Phase 2   EUCTR2014-001753-17-IT   France;Italy;Netherlands;United States
Autologous bone marrow mononuclear cell transplantation
   Neurogen Brain and Spine Institute
      2008   Phase 1   NCT02050776   India
AVI-4658
   AVI BioPharma, Inc.
      2008   -   EUCTR2007-004695-39-GB   United Kingdom
   Imperial College London
      2007   Phase 1/Phase 2   NCT00159250   United Kingdom
   Imperial College, London
      2007   Phase 1;Phase 2   EUCTR2006-003833-33-GB   United Kingdom
   SAREPTA THERAPEUTICS, INC.
      2023   Phase 3   EUCTR2018-001762-42-IT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000337-39-IT   Belgium;France;Italy;United Kingdom
      2017   Phase 2   EUCTR2016-000951-29-IT   Belgium;France;Germany;Italy;United Kingdom
   Sarepta Therapeutics, Inc
      2019   Phase 2   EUCTR2019-000337-39-GB   Belgium;France;United Kingdom
      2019   Phase 2   EUCTR2019-000337-39-BE   Belgium;France;United Kingdom
      2017   Phase 1   EUCTR2016-000951-29-FR   Belgium;France;Germany;Italy;United Kingdom
      2017   Phase 2   EUCTR2016-000951-29-BE   Belgium;France;Germany;Italy;United Kingdom
      -   Phase 2   EUCTR2019-000337-39-FR   Belgium;France;United Kingdom
   Sarepta Therapeutics, Inc.
      2022   Phase 3   EUCTR2018-001762-42-SI   Australia;Canada;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2018-001762-42-RO   Australia;Canada;Colombia;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2018-001762-42-NO   Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2018-001762-42-HU   Australia;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2018-001762-42-GR   Australia;Canada;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2018-001762-42-CZ   Australia;Canada;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2018-001762-42-PL   Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2018-001762-42-SE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Denmark;France;Germany;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Peru;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2018-001762-42-NL   Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2018-001762-42-IE   Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2018-001762-42-DE   Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001762-42-GB   Australia;Belgium;Canada;Colombia;Czechia;Denmark;France;Germany;Ireland;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001762-42-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;France;Germany;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;Peru;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2019   Phase 3   EUCTR2018-001762-42-DK   Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2017   Phase 2   EUCTR2016-000951-29-GB   Belgium;France;Germany;Italy;United Kingdom
      2017   Phase 2   EUCTR2016-000951-29-DE   Belgium;France;Germany;Italy;United Kingdom
      2012   Phase 2   NCT01540409   United States
      2011   Phase 2   NCT01396239   United States
      -   Phase 3   EUCTR2018-001762-42-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom
      -   Phase 2   EUCTR2016-005024-28-Outside-EU/EEA   United States
      -   Phase 2   EUCTR2016-005023-92-Outside-EU/EEA   United States
      -   Phase 3   EUCTR2016-005002-19-Outside-EU/EEA   United States
      -   Phase 2   EUCTR2016-005001-39-Outside-EU/EEA   United States
      -   Phase 2   EUCTR2016-005000-26-Outside-EU/EEA   United States
AVI-4658 FOR injection
   Sarepta Therapeutics
      2009   Phase 1/Phase 2   NCT00844597   United Kingdom
BB-301: dose escalation phase 1B cohort 1
   Benitec Biopharma, Inc.
      2023   Phase 1/Phase 2   NCT06185673   United States
BB-301: dose escalation phase 1B cohort 2
   Benitec Biopharma, Inc.
      2023   Phase 1/Phase 2   NCT06185673   United States
BB-301: dose escalation phase 1B cohort 3
   Benitec Biopharma, Inc.
      2023   Phase 1/Phase 2   NCT06185673   United States
BB-301: dose expansion phase 2A
   Benitec Biopharma, Inc.
      2023   Phase 1/Phase 2   NCT06185673   United States
BBM-D101
   Shanghai Jiao Tong University School of Medicine
      2024   Early Phase 1   NCT06641895   China
BBP-418
   ML Bio Solutions
      -   Phase 2   EUCTR2024-000202-16-Outside-EU/EEA   United States
   ML Bio Solutions, Inc.
      2023   Phase 3   NCT05775848   Australia;Denmark;Germany;Italy;Netherlands;Norway;United Kingdom;United States
      2021   Phase 2   NCT04800874   United States
Beck depression inventory
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
Beetroot juice extract
   Cedars-Sinai Medical Center
      2017   Early Phase 1   NCT02653833   United States
Berg balance scale
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
Betaloc ZOK 100, 95 MG
   Medical University of Gdansk
      2021   Phase 3   EUCTR2020-004901-29-PL   Poland
Betaloc ZOK 25, 23,75 MG
   Medical University of Gdansk
      2021   Phase 3   EUCTR2020-004901-29-PL   Poland
BIO101
   Biophytis
      2020   Phase 1   EUCTR2019-004602-94-BE   Belgium
Biological: umbilical cord based allogenic mesenchymal stem cell
   University of Gaziantep
      2015   Phase 1   NCT02484560   Turkey
Bisoprolol
   Newcastle upon Tyne Hospitals NHS Foundation Trust
      2009   Phase 3   EUCTR2007-005932-10-GB   United Kingdom
Bisoprolol fumarate
   Peking Union Medical College Hospital
      2019   Phase 2/Phase 3   NCT03779646   China
Bisphosphonate treatment
   Gilles Boire
      2001   Phase 4   NCT01882400   Canada
Blood assays
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT05558813   France
Blood sample
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT06147414   France
BLS-M22
   BioLeaders Corporation
      2019   Phase 1   NCT03789734   Korea, Republic of
BMN 044
   BIOMARIN PHARMACEUTICAL INC.
      -   Phase 2   EUCTR2015-003681-87-IT   Belgium;Italy;Netherlands;Sweden;United States
   BioMarin Pharmaceutical Inc.
      2016   Phase 2   EUCTR2015-003681-87-BE   Belgium;Italy;Netherlands;Sweden;United States
BMN 044 IV 6 MG/KG
   BioMarin Pharmaceutical
      2016   Phase 2   NCT02958202   Belgium;Italy;Netherlands;Sweden
BMN 044 IV 9 MG/KG
   BioMarin Pharmaceutical
      2016   Phase 2   NCT02958202   Belgium;Italy;Netherlands;Sweden
BMN 044 SC 6 MG/KG
   BioMarin Pharmaceutical
      2016   Phase 2   NCT02958202   Belgium;Italy;Netherlands;Sweden
BMN 045
   BioMarin Pharmaceutical Inc.
      2013   Phase 1;Phase 2   EUCTR2011-005040-10-GB   Belgium;France;Italy;United Kingdom
BMN 053
   BioMarin Pharmaceutical Inc.
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States
BMN 351
   BioMarin Pharmaceutical
      2024   Phase 1/Phase 2   NCT06280209   Italy;Netherlands;Spain;Turkey;United Kingdom
BMN053
   BioMarin Nederland B.V.
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States
BMS-986089-01 (RO7239361) , ANTI-myostatin
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
BMS-986089-01 (RO7239361), ANTI-myostatin
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
BMS-986089-01, ANTI-myostatin
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001654-18-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001654-18-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-SE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-NL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
Bocidelpar
   Astellas Pharma Inc
      2021   Phase 1   NCT04184882   United States
Botulinum toxin type A
   Rigshospitalet
      2014   Phase 2   EUCTR2014-002210-23-DK   Denmark
Brief pain inventory short-form
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
Cabaletta
   Bioblast Pharma Ltd.
      2014   Phase 2   NCT02015481   Canada;Israel;United States
Calcichew D3 forte
   The Central Remedial Clinic and The Children's University Hospital
      2010   Phase 2   EUCTR2009-017649-67-IE   Ireland
Calcifediol
   Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2008   -   EUCTR2007-005808-41-ES   Spain
Canakinumab
   Children's National Research Institute
      2019   Phase 1/Phase 2   NCT03936894   United States
CAP-1002
   Capricor Inc.
      2022   Phase 3   NCT05126758   United States
      2020   Phase 2   NCT04428476   United States
      2018   Phase 2   NCT06304064   United States
      2018   Phase 2   NCT03406780   United States
      2016   Phase 2   NCT02485938   United States
Cardiac MRI
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT05558813   France
Cardiovascular profile
   Monica Levy Andersen
      2013   -   NCT01921374   Brazil
Carvedilol
   Catholic University, Italy
      2008   Phase 4   NCT00819845   Italy
   Department Of Paediatric Cardiology
      -   Phase 4   EUCTR2006-003075-12-IE   Ireland
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2008   -   EUCTR2008-007236-18-IT   Italy
   Suzuka Hospital
      2007   Phase 4   NCT00606775   Japan
Casimersen
   SAREPTA THERAPEUTICS, INC.
      2018   Phase 3   EUCTR2017-004625-32-IT   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
   Sarepta Therapeutics, Inc.
      2020   Phase 3   EUCTR2017-004625-32-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-004625-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2019   -   NCT06606340   United States
      2019   Phase 3   EUCTR2017-004625-32-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004625-32-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   NCT03532542   Belgium;Bulgaria;Canada;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-GB   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-ES   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
CAT-1004
   Catabasis Pharmaceuticals Inc.
      2020   Phase 3   EUCTR2019-003563-22-SE   Australia;Canada;Germany;Ireland;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003563-22-IE   Australia;Canada;Germany;Ireland;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003563-22-GB   Australia;Canada;Germany;Ireland;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003563-22-DE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States
   Catabasis Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-000464-29-IE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000464-29-DE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000464-29-SE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States
Chronic corticosteroid therapy
   PTC Therapeutics
      2010   Phase 2   NCT01009294   United Kingdom;United States
Cialis 10 MG FILM-coated tablets
   Eli Lilly and Company
      2013   -   EUCTR2013-001194-25-NL   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-IT   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001194-25-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001194-25-DE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-BE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Lilly S.A.
      2013   Phase 3   EUCTR2013-001194-25-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
Cialis 2.5 MG FILM-coated tablets
   Eli Lilly and Company
      2013   -   EUCTR2013-001194-25-NL   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-IT   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001194-25-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001194-25-DE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-BE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Lilly S.A.
      2013   Phase 3   EUCTR2013-001194-25-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
Cialis 20 MG FILM-coated tablets
   Eli Lilly and Company
      2013   -   EUCTR2013-001194-25-NL   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-IT   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001194-25-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001194-25-DE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-BE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Lilly S.A.
      2013   Phase 3   EUCTR2013-001194-25-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
Cialis 5 MG FILM-coated tablets
   Eli Lilly and Company
      2013   -   EUCTR2013-001194-25-NL   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-IT   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001194-25-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001194-25-DE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-BE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Lilly S.A.
      2013   Phase 3   EUCTR2013-001194-25-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
Citrulline
   University Hospital, Basel, Switzerland
      2013   Phase 3   NCT01995032   Switzerland
Clenbuterol
   Jeffrey Statland
      2025   Phase 1   NCT06721299   United States
Coenzyme Q10
   Cooperative International Neuromuscular Research Group
      2007   Phase 3   NCT00308113   Australia;Puerto Rico;United States
      2001   Phase 2   NCT00033189   United States
Coenzyme Q10 and lisinopril
   Cooperative International Neuromuscular Research Group
      2010   Phase 2/Phase 3   NCT01126697   Canada;Japan;United States
Complete physical examination
   Hospital Universitari Vall d'Hebron Research Institute
      2021   -   NCT06924125   Spain
Concurrent exercise training
   McMaster University
      2024   Phase 3   NCT05848830   Canada
Control group typically developing
   University of Sao Paulo
      2013   -   NCT04740554   -
Corticosteroid
   Sarepta Therapeutics, Inc.
      2025   Phase 3   NCT06952686   -
Corticosteroide
   F. HOFFMANN - LA ROCHE LTD.
      2022   Phase 2   EUCTR2022-000691-19-IT   Belgium;France;Germany;Italy;Spain;United Kingdom
   SAREPTA THERAPEUTICS, INC.
      2023   Phase 3   EUCTR2020-002372-13-IT   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
Corticosteroids
   FibroGen
      2020   Phase 3   NCT04632940   Australia;Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   NCT04371666   Australia;Austria;Belgium;Canada;China;Czechia;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Cosintropina acetato
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
Cosyntropin
   Mallinckrodt ARD LLC
      2018   Phase 2   NCT03400852   Bulgaria;Israel;Italy;Mexico;Serbia;Spain;Turkey;United States
Cosyntropin acetate
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
   Mallinckrodt ARD Inc.
      2018   Phase 2   EUCTR2017-004139-35-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004139-35-BG   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004139-35-BE   Argentina;Belgium;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States
CR13C
   Radboud University Nijmegen Medical Center
      2007   -   EUCTR2006-006776-37-NL   Netherlands
CRD-TMH-001
   Cure Rare Disease, Inc
      2022   Phase 1   NCT05514249   United States
CRD007
   Cardoz AB
      2012   Phase 2   NCT01540604   Sweden
      2011   -   EUCTR2011-004667-76-SE   Sweden
Creatine monohydrate
   Cooperative International Neuromuscular Research Group
      2000   Phase 2/Phase 3   NCT00016653   Belgium;Israel;Puerto Rico;United States
   National Center for Research Resources (NCRR)
      2001   Phase 3   NCT00018109   United States
Creatine-13C
   Radboud University Nijmegen Medical Center
      2007   -   EUCTR2006-006776-37-NL   Netherlands
Cyclosporin A
   Universitätsklinik Freiburg
      2005   Phase 2;Phase 3   EUCTR2005-000663-26-AT   Austria
Decortin
   Universitätsklinik Freiburg
      2005   Phase 2;Phase 3   EUCTR2005-000663-26-AT   Austria
Deflan*10CPR 6MG
   AZIENDA OSPEDALIERA DI PADOVA
      2013   -   EUCTR2010-023744-33-IT   Canada;Italy;United Kingdom;United States
Deflazacort
   AZIENDA OSPEDALIERA DI PADOVA
      2013   -   EUCTR2010-023744-33-IT   Canada;Italy;United Kingdom;United States
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2020   Phase 2   EUCTR2019-004426-24-IT   Italy
   PTC Therapeutics
      2019   Phase 3   NCT03783923   Canada;Denmark;France;Germany;Norway;Russian Federation;Sweden;United States
      2019   -   NCT02592941   United States
      2018   Phase 3   NCT03642145   United States
      2014   Phase 1   NCT02295748   United States
      2014   Phase 1   NCT02251600   United States
   PTC Therapeutics, Inc.
      2019   Phase 3   EUCTR2018-004740-36-FR   Canada;Denmark;France;Germany;Norway;Sweden;United States
      2019   Phase 3   EUCTR2018-004740-36-DK   Canada;Denmark;France;Germany;Norway;Russian Federation;Sweden;United States
      2019   Phase 3   EUCTR2018-004740-36-DE   Canada;Denmark;France;Germany;Norway;Russian Federation;Sweden;United States
Deflazacort 6 MG tablets
   University of Rochester
      2012   -   EUCTR2010-023744-33-GB   Canada;Germany;Italy;United Kingdom;United States
Dehydroepiandrosterone 100 and 400 MG
   University of Versailles
      2004   Phase 2/Phase 3   NCT00167609   France
Delandistrogene moxeparvovec
   F. HOFFMANN - LA ROCHE LTD.
      2022   Phase 2   EUCTR2022-000691-19-IT   Belgium;France;Germany;Italy;Spain;United Kingdom
   F. Hoffmann-La Roche Ltd
      2023   Phase 2   EUCTR2022-000691-19-FR   Belgium;France;Germany;Italy;Spain;United Kingdom
      2023   Phase 2   EUCTR2022-000691-19-DE   Belgium;France;Germany;Italy;Spain;United Kingdom
   Hoffmann-La Roche
      2023   Phase 2   NCT06128564   Belgium;France;Germany;Italy;Spain;United Kingdom
   SAREPTA THERAPEUTICS, INC.
      2023   Phase 3   EUCTR2020-002372-13-IT   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
   Sarepta Therapeutics, Inc
      2023   Phase 1   EUCTR2022-003407-15-ES   Spain
   Sarepta Therapeutics, Inc.
      2024   Phase 1   NCT06597656   United States
      2024   -   NCT06270719   United States
      2024   Phase 1   NCT06241950   Spain
      2023   Phase 3   NCT05967351   Belgium;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
      2023   Phase 3   NCT05881408   Australia;Belgium;Germany;Hong Kong;Israel;Italy;Japan;Korea, Republic of;Spain;Sweden;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2020-002372-13-FR   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2020-002372-13-BE   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002372-13-SE   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   NCT05096221   Belgium;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
      2020   Phase 1   NCT04626674   United States
      2018   Phase 1/Phase 2   NCT03769116   United States
      2018   Phase 1/Phase 2   NCT03375164   United States
Deltacortene*20CPR 5MG
   AZIENDA OSPEDALIERA DI PADOVA
      2013   -   EUCTR2010-023744-33-IT   Canada;Italy;United Kingdom;United States
Dexmedetomidine
   Nationwide Children's Hospital
      2011   -   NCT01645098   United States
Dilatrend
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2008   -   EUCTR2008-007236-18-IT   Italy
DM1-activc
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
Dosing extension
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01957059   Belgium;France;Italy;Netherlands;United Kingdom
Drisapersen
   BioMarin Nederland BV
      2015   Phase 3   EUCTR2015-001955-54-NL   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay
   BioMarin Pharmaceutical
      2015   -   NCT02636686   Argentina;Australia;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   NCT01803412   Canada;United States
      2008   Phase 2   NCT01910649   -
   GlaxoSmithKline
      2014   Phase 3   NCT01890798   -
   Prosensa Therapeutics BV
      2008   Phase 1;Phase 2   EUCTR2007-004819-54-SE   Belgium;Netherlands;Sweden
      2008   Phase 1;Phase 2   EUCTR2007-004819-54-BE   Belgium;Netherlands;Sweden
Drisapersen sodium
   BioMarin Pharmaceutical Inc.
      2016   Phase 3   EUCTR2015-001955-54-DE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay
      2016   Phase 3   EUCTR2015-001955-54-BE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay
      2016   Phase 3   EUCTR2014-005296-81-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001955-54-ES   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay
DS-5141B
   DAIICHI SANKYO Co.,Ltd.
      2020   Phase 2   JPRN-jRCT2080225225   Japan
   Daiichi Sankyo Co., Ltd.
      2020   Phase 2   NCT04433234   Japan
      2015   Phase 1/Phase 2   NCT02667483   Japan
DT-DEC01
   Dystrogen Therapeutics Technology Polska Spólka z Ograniczona Odpowiedzialnoscia
      2023   Phase 1;Phase 2   EUCTR2022-003126-42-PL   Poland
Duchenne muscular dystrophy group with deflazacort
   University of Sao Paulo
      2013   -   NCT04740554   -
Duchenne muscular dystrophy group with prednisone/predisolone
   University of Sao Paulo
      2013   -   NCT04740554   -
Duchenne muscular dystrophy group without corticosteroids therapy
   University of Sao Paulo
      2013   -   NCT04740554   -
DYNE-101
   Dyne Therapeutics
      2022   Phase 1/Phase 2   NCT05481879   France;Germany;Italy;Netherlands;New Zealand;United Kingdom
DYNE-251
   Dyne Therapeutics
      2022   Phase 1/Phase 2   NCT05524883   Australia;Belgium;Canada;Ireland;Italy;Korea, Republic of;Spain;United Kingdom;United States
   Dyne Therapeutics, Inc
      2022   Phase 1;Phase 2   EUCTR2021-005478-24-ES   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Spain;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2021-005478-24-BE   Australia;Belgium;Canada;Ireland;Italy;Spain;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2021-005478-24-IE   Australia;Belgium;Canada;Ireland;Italy;Spain;United Kingdom;United States
Dystrophin levels
   PTC Therapeutics
      2019   Phase 2   NCT03796637   United States
Edasalonexent
   Catabasis Pharmaceuticals
      2019   Phase 3   NCT03917719   Australia;Canada;Germany;Sweden;United Kingdom;United States
      2018   Phase 3   NCT03703882   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States
      2016   Phase 1/Phase 2   NCT02439216   United States
   Catabasis Pharmaceuticals Inc.
      2020   Phase 3   EUCTR2019-003563-22-SE   Australia;Canada;Germany;Ireland;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003563-22-IE   Australia;Canada;Germany;Ireland;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003563-22-GB   Australia;Canada;Germany;Ireland;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003563-22-DE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States
   Catabasis Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-000464-29-IE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000464-29-DE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000464-29-SE   Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom;United States
EMD 87580
   ESPERARE FOUNDATION
      2017   Phase 1   EUCTR2015-002530-50-IT   France;Italy;Spain;United Kingdom
   EspeRare
      2015   Phase 1   EUCTR2015-002530-50-GB   France;Italy;Spain;Switzerland;United Kingdom
      2015   Phase 1   EUCTR2015-002530-50-FR   France;Italy;Spain;Switzerland;United Kingdom
      2015   Phase 1   EUCTR2015-002530-50-ES   France;Italy;Spain;Switzerland;United Kingdom
Emea/H/C/000638
   Rigshospitalet
      2011   -   EUCTR2010-024659-10-DK   Denmark
Empagliflozin tablets
   Sebastiano Lava
      2025   Phase 2   NCT06643442   United Kingdom
EN001
   ENCell
      2024   Phase 1/Phase 2   NCT06328725   Korea, Republic of
      2022   Phase 1   NCT05338099   Korea, Republic of
Enahexal®, 10MG
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany
Enalapril
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany
   InCor Heart Institute
      2009   Phase 3   NCT02432885   -
Enalhexal®, 5 MG
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany
END-OF-life nursing education consortium-pediatric palliative care AS WEB based-training plus usual care
   Altoosi University College
      2020   -   NCT04461561   Iraq
EPA and DHA
   Coordinación de Investigación en Salud, Mexico
      2013   -   NCT01826422   Mexico
EPI-321
   Epicrispr Biotechnologies, Inc.
      2025   Phase 1/Phase 2   NCT06907875   New Zealand;United States
Epicatechin
   Craig McDonald, MD
      2016   Phase 2   NCT03236662   United States
      2016   Phase 1/Phase 2   NCT02964377   United States
      2013   Phase 1/Phase 2   NCT01856868   United States
   Epirium Bio Inc.
      2020   Phase 1   NCT04386304   United States
Epigallocatechin-gallate
   Charite University, Berlin, Germany
      2010   Phase 2/Phase 3   NCT01183767   Germany
Eplerenone
   Ohio State University
      2015   Phase 3   NCT02354352   United States
   Subha Raman
      2012   -   NCT01521546   United States
ERX-963
   Expansion Therapeutics, Inc.
      2019   Phase 1   NCT03959189   United States
Esomeprazole
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2020   Phase 2   EUCTR2019-004426-24-IT   Italy
Esomeprazolo
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2020   Phase 2   EUCTR2019-004426-24-IT   Italy
Eteplirsen
   SAREPTA THERAPEUTICS, INC.
      2023   Phase 3   EUCTR2018-001762-42-IT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000337-39-IT   Belgium;France;Italy;United Kingdom
      2017   Phase 2   EUCTR2016-000951-29-IT   Belgium;France;Germany;Italy;United Kingdom
   Sarepta Therapeutics, Inc
      2019   Phase 2   EUCTR2019-000337-39-GB   Belgium;France;United Kingdom
      2019   Phase 2   EUCTR2019-000337-39-BE   Belgium;France;United Kingdom
      2017   Phase 1   EUCTR2016-000951-29-FR   Belgium;France;Germany;Italy;United Kingdom
      2017   Phase 2   EUCTR2016-000951-29-BE   Belgium;France;Germany;Italy;United Kingdom
      -   Phase 2   EUCTR2019-000337-39-FR   Belgium;France;United Kingdom
   Sarepta Therapeutics, Inc.
      2022   Phase 3   EUCTR2018-001762-42-SI   Australia;Canada;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2018-001762-42-RO   Australia;Canada;Colombia;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2018-001762-42-NO   Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2018-001762-42-HU   Australia;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2018-001762-42-GR   Australia;Canada;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2018-001762-42-CZ   Australia;Canada;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2018-001762-42-PL   Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2020   Phase 3   NCT03992430   Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2018-001762-42-SE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Denmark;France;Germany;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Peru;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2018-001762-42-NL   Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2018-001762-42-IE   Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2018-001762-42-DE   Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2019   -   NCT06606340   United States
      2019   Phase 2   NCT03985878   Belgium;France;Italy;United Kingdom
      2019   Phase 3   EUCTR2018-001762-42-GB   Australia;Belgium;Canada;Colombia;Czechia;Denmark;France;Germany;Ireland;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001762-42-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;France;Germany;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;Peru;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2019   Phase 3   EUCTR2018-001762-42-DK   Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2017   Phase 2   NCT03218995   Belgium;France;Germany;Italy;United Kingdom
      2017   Phase 2   EUCTR2016-000951-29-GB   Belgium;France;Germany;Italy;United Kingdom
      2017   Phase 2   EUCTR2016-000951-29-DE   Belgium;France;Germany;Italy;United Kingdom
      2015   Phase 2   NCT02420379   United States
      2014   Phase 2   NCT02286947   United States
      2014   Phase 3   NCT02255552   United States
      2012   Phase 2   NCT01540409   United States
      2011   Phase 2   NCT01396239   United States
      -   Phase 3   EUCTR2018-001762-42-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom
Eteplirsen injection
   Sarepta Therapeutics, Inc.
      -   Phase 2   EUCTR2016-005024-28-Outside-EU/EEA   United States
      -   Phase 2   EUCTR2016-005023-92-Outside-EU/EEA   United States
      -   Phase 3   EUCTR2016-005002-19-Outside-EU/EEA   United States
      -   Phase 2   EUCTR2016-005001-39-Outside-EU/EEA   United States
      -   Phase 2   EUCTR2016-005000-26-Outside-EU/EEA   United States
Eucardic
   Department Of Paediatric Cardiology
      -   Phase 4   EUCTR2006-003075-12-IE   Ireland
EV substance code: SUB188638
   ReveraGen BioPharma Inc.
      2018   Phase 2   EUCTR2017-003568-10-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States
Exercise training
   University of Florida
      2024   Phase 2   NCT06290713   United States
Exondys 51
   Kevin Flanigan
      2020   Phase 2   NCT04179409   United States
   SAREPTA THERAPEUTICS, INC.
      2017   Phase 2   EUCTR2016-000951-29-IT   Belgium;France;Germany;Italy;United Kingdom
   Sarepta Therapeutics, Inc
      2019   Phase 2   EUCTR2019-000337-39-BE   Belgium;France;United Kingdom
      2017   Phase 1   EUCTR2016-000951-29-FR   Belgium;France;Germany;Italy;United Kingdom
      -   Phase 2   EUCTR2019-000337-39-FR   Belgium;France;United Kingdom
   Sarepta Therapeutics, Inc.
      2019   Phase 3   EUCTR2018-001762-42-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;France;Germany;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;Peru;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2019   Phase 3   EUCTR2018-001762-42-DK   Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Italy;Jordan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Poland;Romania;Serbia;Slovenia;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2018-001762-42-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom
      -   Phase 2   EUCTR2016-005024-28-Outside-EU/EEA   United States
      -   Phase 2   EUCTR2016-005023-92-Outside-EU/EEA   United States
      -   Phase 3   EUCTR2016-005002-19-Outside-EU/EEA   United States
      -   Phase 2   EUCTR2016-005001-39-Outside-EU/EEA   United States
      -   Phase 2   EUCTR2016-005000-26-Outside-EU/EEA   United States
Ezutromid
   Summit Therapeutics
      2016   Phase 2   NCT02858362   United Kingdom;United States
Fatigue and daytime sleepiness scale
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
FG-3019
   FIBROGEN
      2021   Phase 3   EUCTR2020-000699-39-IT   Australia;Austria;Belgium;Canada;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000698-26-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
   FibroGen, Inc.
      2023   Phase 3   EUCTR2020-000698-26-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-000698-26-BE   Austria;Belgium;China;Czech Republic;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000699-39-NL   Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;United States
      2021   Phase 3   EUCTR2020-000699-39-FR   Australia;Austria;Belgium;Canada;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000699-39-ES   Australia;Austria;Belgium;Canada;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000699-39-BE   Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;United States
      2021   Phase 3   EUCTR2020-000699-39-AT   Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;United States
      2021   Phase 3   EUCTR2020-000698-26-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000698-26-AT   Austria;Belgium;China;Czech Republic;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000698-26-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000698-26-ES   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000698-26-CZ   Austria;Belgium;China;Czech Republic;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Filgrastim
   Medical University of Bialystok
      2013   Phase 1   NCT02814110   Poland
Flavocoxid
   University of Messina
      2011   Phase 1   NCT01335295   Italy
Fordadistrogene movaparvovec
   Pfizer
      2023   Phase 3   NCT05689164   United States
   Pfizer Inc.
      2022   Phase 3   EUCTR2019-002921-31-DE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-002921-31-BE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
Fragment antibody targeting human TFR1 conjugated TO phosphorodiamidate morpholino oligomer
   Dyne Therapeutics, Inc
      2022   Phase 1;Phase 2   EUCTR2021-005478-24-ES   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Spain;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2021-005478-24-BE   Australia;Belgium;Canada;Ireland;Italy;Spain;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2021-005478-24-IE   Australia;Belgium;Canada;Ireland;Italy;Spain;United Kingdom;United States
FTX-1821
   Fulcrum Therapeutics
      2022   Phase 3   EUCTR2022-000389-16-FR   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000389-16-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000389-16-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2022-000389-16-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   Fulcrum Therapeutics, Inc.
      2022   Phase 3   EUCTR2022-000389-16-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001181-15-FR   France;Germany;Spain;United States
      2019   Phase 2   EUCTR2019-001181-15-ES   France;Germany;Spain;United States
Functional index-2
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
GEN6050X intravenous injection
   Peking Union Medical College Hospital
      2024   Early Phase 1   NCT06392724   China
Genetic characterization
   Nationwide Children's Hospital
      2016   -   NCT02972580   United States
Gentamicin
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 1   NCT00005574   United States
Gentamicin infusions twice A week FOR SIX months
   Nationwide Children's Hospital
      2007   Phase 1   NCT00451074   United States
Givinostat
   ITALFARMACO
      2013   Phase 2   EUCTR2012-002566-12-IT   Italy
   ITALFARMACO S.P.A.
      2018   Phase 2   EUCTR2017-001629-41-NL   Italy;Netherlands
      2017   Phase 2   EUCTR2017-001629-41-IT   Italy;Netherlands
   ITALFARMACO S.p.A.
      2020   Phase 3   EUCTR2017-000397-10-GB   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000397-10-NL   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000397-10-FR   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000397-10-ES   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000397-10-BE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000397-10-IT   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-NL   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-IT   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-GB   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-ES   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-DE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-BE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-000397-10-DE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2016-000401-36-FR   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States
   Italfarmaco
      2024   Phase 3   NCT05933057   Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom
      2017   Phase 2/Phase 3   NCT03373968   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      2017   Phase 2   NCT03238235   Italy;Netherlands
      2017   Phase 3   NCT02851797   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      2013   Phase 1/Phase 2   NCT01761292   Italy
Givinostat hydrochloride - cohort 2
   Italfarmaco
      2025   Phase 2   NCT06769633   Belgium;Italy;Netherlands;United Kingdom
Glucocorticoid
   Sarepta Therapeutics, Inc.
      2024   Phase 3   NCT06246513   United Kingdom;United States
Glutamine
   Cooperative International Neuromuscular Research Group
      2000   Phase 2/Phase 3   NCT00016653   Belgium;Israel;Puerto Rico;United States
   National Center for Research Resources (NCRR)
      2001   Phase 3   NCT00018109   United States
GNT0004
   Genethon
      2020   Phase 1;Phase 2;Phase 3   EUCTR2020-002093-27-FR   France;Israel;United Kingdom;United States
GNT0006
   Atamyo Therapeutics
      2022   Phase 1;Phase 2   EUCTR2021-004276-33-FR   Canada;Denmark;France;Germany;Norway;Sweden;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2021-004276-33-DK   Canada;Denmark;France;Germany;Norway;Sweden;United Kingdom;United States
Golodirsen
   Rare Disease Research, LLC
      2020   Phase 4   NCT04708314   United States
   SAREPTA THERAPEUTICS, INC.
      2018   Phase 3   EUCTR2017-004625-32-IT   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
   Sarepta Therapeutics, Inc.
      2020   Phase 3   EUCTR2017-004625-32-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-004625-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2019   -   NCT06606340   United States
      2019   Phase 3   EUCTR2017-004625-32-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004625-32-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   NCT03532542   Belgium;Bulgaria;Canada;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-GB   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-ES   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
Growth hormone
   West China Second Hospital of Sichuan University
      2023   Phase 1   ChiCTR2300078104   China
Gsgc
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
GSK2402968
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-001266-17-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
   GlaxoSmithKline
      2011   Phase 3   NCT01480245   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2010   Phase 2   NCT01153932   Australia;Belgium;France;Germany;Israel;Netherlands;Spain;Turkey;United Kingdom
   GlaxoSmithKline Research and Development LTD
      2012   -   EUCTR2011-001266-17-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2012   Phase 3   EUCTR2011-001266-17-DK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2012   -   EUCTR2011-001266-17-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2012   -   EUCTR2011-001266-17-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2012   Phase 3   EUCTR2010-020069-26-HU   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan
      2011   -   EUCTR2011-001266-17-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2011   Phase 3   EUCTR2011-001266-17-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2011   -   EUCTR2011-001266-17-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2011   Phase 3   EUCTR2011-001266-17-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      2011   -   EUCTR2010-020069-26-PL   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan
      2011   -   EUCTR2010-020069-26-NL   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain
      2011   -   EUCTR2010-020069-26-DK   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan
      2011   -   EUCTR2010-020069-26-CZ   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan
      2011   Phase 3   EUCTR2010-020069-26-BE   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain
      2010   -   EUCTR2010-020069-26-IT   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain
      2010   Phase 3   EUCTR2010-020069-26-FR   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Spain
      2010   -   EUCTR2010-018412-32-NL   France;Germany;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2010-018412-32-GB   Australia;France;Germany;Israel;Netherlands;Spain;Turkey;United Kingdom
      2010   Phase 2   EUCTR2010-018412-32-FR   Belgium;France;Germany;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2010-018412-32-ES   France;Germany;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2010-018412-32-DE   Australia;France;Germany;Israel;Netherlands;Spain;Turkey;United Kingdom
      2010   Phase 2   EUCTR2010-018412-32-BE   Australia;Belgium;France;Germany;Israel;Netherlands;Spain;Turkey;United Kingdom
      -   -   EUCTR2011-001266-17-Outside-EU/EEA   -
      -   Phase 3   EUCTR2011-001266-17-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
      -   -   EUCTR2010-024566-22-Outside-EU/EEA   United States
      -   Phase 1   EUCTR2010-024566-22-FR   France
      -   -   EUCTR2010-020069-26-Outside-EU/EEA   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan
      -   Phase 3   EUCTR2010-020069-26-NO   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Spain
      -   -   EUCTR2010-020069-26-DE   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan
      -   -   EUCTR2010-018412-32-Outside-EU/EEA   Australia;Israel;Turkey
   GlaxoSmithKline, S.A.
      2011   -   EUCTR2011-001266-17-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey;United Kingdom
   GlaxoSmithKline.S.A.
      2011   Phase 3   EUCTR2010-020069-26-ES   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Spain
GSK2402968 3MG/KG/week
   GlaxoSmithKline
      2011   Phase 2   NCT01462292   United States
GSK2402968 6 MG/KG/week
   GlaxoSmithKline
      2011   Phase 2   NCT01462292   United States
GSK2402968 6MG/KG/week
   GlaxoSmithKline
      2010   Phase 3   NCT01254019   Argentina;Belgium;Brazil;Canada;Chile;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Taiwan;Turkey
GYM329
   F.Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2021-006255-34-DK   Denmark;Italy;United Kingdom;United States
H44aon188
   Prosensa Therapeutics B.V
      2010   -   EUCTR2009-013762-63-SE   Belgium;Italy;Netherlands;Sweden
      2010   -   EUCTR2009-013762-63-NL   Belgium;Italy;Netherlands;Sweden
      2009   Phase 1;Phase 2   EUCTR2009-013762-63-BE   Belgium;Italy;Netherlands;Sweden
H51aon23
   Prosensa Holding B.V.
      2008   -   EUCTR2007-004819-54-NL   Belgium;Netherlands;Sweden
Haemostasis tests
   Assistance Publique - Hôpitaux de Paris
      2018   -   NCT03424460   France
Hand opening time
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
HG302
   HuidaGene Therapeutics Co., Ltd.
      2024   -   NCT06594094   China
Hidroferol
   Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2008   -   EUCTR2007-005808-41-ES   Spain
HLA-identical allogeneic mesoangioblasts
   FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
      2011   -   EUCTR2011-000176-33-IT   Italy
Hmabs
   FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
      2011   -   EUCTR2011-000176-33-IT   Italy
Hormonal profile
   Monica Levy Andersen
      2013   -   NCT01921374   Brazil
HT-100
   Akashi Therapeutics
      2015   Phase 2   NCT02525302   United States
   Processa Pharmaceuticals
      2013   Phase 2   NCT01978366   United States
      2013   Phase 1/Phase 2   NCT01847573   United States
Human umbilical cord mesenchymal stem cells
   MED Institute Inc.
      2023   -   NCT06579352   United States
   Shenzhen Beike Bio-Technology Co., Ltd.
      2011   Phase 1/Phase 2   NCT01610440   China
Ibuprofen
   PARENT PROJECT ONLUS
      2014   -   EUCTR2013-004427-37-IT   Italy
Ibuprofen and isosorbide dinitrate combination
   Parent Project, Italy
      2011   Phase 1   NCT01478022   Italy
Idebenone
   SANTHERA PHARMACEUTICALS
      2018   Phase 3   EUCTR2017-004279-30-IT   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
   SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD
      2012   -   EUCTR2009-012037-30-IT   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United States
   Santhera Pharmaceuticals
      2018   -   NCT03433807   United States
      2009   Phase 3   NCT01027884   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2008   Phase 2   NCT00758225   Belgium
      2005   Phase 2   NCT00654784   Belgium
   Santhera Pharmaceuticals (Switzerland) Limited
      2020   Phase 3   EUCTR2017-004279-30-NL   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2016-000602-10-BG   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004279-30-AT   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004279-30-GB   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004279-30-ES   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004279-30-BE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2016-000602-10-HU   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000602-10-NL   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-GB   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-FR   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-ES   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-DE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-BE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-AT   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   -   EUCTR2009-012037-30-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2010   -   EUCTR2009-012037-30-SE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2010   Phase 3   EUCTR2009-012037-30-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2010   -   EUCTR2009-012037-30-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden
      2010   -   EUCTR2009-012037-30-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2009   -   EUCTR2009-012037-30-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2009   Phase 3   EUCTR2009-012037-30-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      -   Phase 3   EUCTR2017-004279-30-SE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2017-004279-30-FR   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2017-004279-30-DE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-000602-10-SE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-000602-10-IE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
   Santhera Pharmaceuticals (Switzerland) Ltd
      2008   -   EUCTR2007-007752-34-BE   Belgium
   Santhera Pharmaceuticals LLC
      2005   -   EUCTR2005-002520-33-BE   Belgium
Idebenone 150 MG FILM-coated tablets
   Santhera Pharmaceuticals
      2018   Phase 3   NCT03603288   Austria;Belgium;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2016   Phase 3   NCT02814019   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Idefirix
   Sarepta Therapeutics, Inc
      2023   Phase 1   EUCTR2022-003407-15-ES   Spain
Ifetroban
   Cumberland Pharmaceuticals
      2020   Phase 2   NCT03340675   United States
IGF-1
   Children's Hospital Medical Center, Cincinnati
      2010   Phase 1/Phase 2   NCT01207908   United States
Imlifidase
   Sarepta Therapeutics, Inc
      2023   Phase 1   EUCTR2022-003407-15-ES   Spain
   Sarepta Therapeutics, Inc.
      2024   Phase 1   NCT06241950   Spain
IN-home exercise training
   University of Florida
      2020   Phase 2   NCT04322357   United States
Increased exercise intensity
   Cedars-Sinai Medical Center
      2013   Phase 2/Phase 3   NCT02147639   United States
Inflammatory profile
   Monica Levy Andersen
      2013   -   NCT01921374   Brazil
INS1201
   Insmed Gene Therapy LLC
      2025   Phase 1   NCT06817382   United States
Ionis-dmpkrx
   Ionis Pharmaceuticals, Inc.
      2014   Phase 1/Phase 2   NCT02312011   United States
Isosorbide dinitrate 20 MG
   PARENT PROJECT ONLUS
      2014   -   EUCTR2013-004427-37-IT   Italy
Isosorbide dinitrate 40 MG
   PARENT PROJECT ONLUS
      2014   -   EUCTR2013-004427-37-IT   Italy
Isosorbide dinitrate 60 MG
   PARENT PROJECT ONLUS
      2014   -   EUCTR2013-004427-37-IT   Italy
Isosorbide dinitrate 80 MG
   PARENT PROJECT ONLUS
      2014   -   EUCTR2013-004427-37-IT   Italy
ITF2357
   ITALFARMACO
      2013   Phase 2   EUCTR2012-002566-12-IT   Italy
   ITALFARMACO S.P.A.
      2018   Phase 2   EUCTR2017-001629-41-NL   Italy;Netherlands
      2017   Phase 2   EUCTR2017-001629-41-IT   Italy;Netherlands
   ITALFARMACO S.p.A.
      2020   Phase 3   EUCTR2017-000397-10-GB   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000397-10-NL   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000397-10-FR   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000397-10-ES   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000397-10-BE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000397-10-IT   Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-NL   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-IT   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-GB   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-ES   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-DE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000401-36-BE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-000397-10-DE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Serbia;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2016-000401-36-FR   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States
ITF2357 10 MG/ML
   Italfarmaco
      2021   Phase 1   NCT04821063   Canada
IV infusion
   Nippon Shinyaku Co., Ltd.
      2020   Phase 3   JPRN-jRCT2080224893   Asia except Japan;Europe;Japan;North America;Oceania;South America
   PepGen Inc
      2024   Phase 2   NCT06833931   United Kingdom
JWK007 single intravenous infusion administration
   West China Hospital
      2024   Phase 1   NCT06114056   China
Ketamine
   Nationwide Children's Hospital
      2011   -   NCT01645098   United States
L-arginine
   Massachusetts General Hospital
      2012   Phase 1   NCT01388764   United States
   University Hospital, Basel, Switzerland
      2012   Phase 1   NCT02516085   -
L-citrulline and metformin & L-citrulline
   University Hospital, Basel, Switzerland
      2013   Phase 2   NCT02018731   Switzerland
L-glutamine
   Assistance Publique - Hôpitaux de Paris
      2006   Phase 2   NCT00296621   France
Laboratory tests
   National Hospital Organization Toneyama National Hospital
      2018   -   JPRN-UMIN000031965   Japan
   Turkish Society of Pediatric Gastroenterology, Hepatology and Nutrition
      2019   -   NCT04120168   Turkey
Lamotrigin actavis
   Grete Andersen
      2013   -   EUCTR2013-003309-24-DK   Denmark
Lamotrigine
   Grete Andersen
      2013   -   EUCTR2013-003309-24-DK   Denmark
   Grete Andersen, MD
      2013   Phase 3   NCT01939561   Denmark
LE051
   Shanghai Jiao Tong University School of Medicine
      2024   Early Phase 1   NCT06900049   China
Lentiviral vector trans-skip gene modified autologous mesoangioblasts
   The University of Manchester
      2019   Phase 1   EUCTR2019-001825-28-GB   United Kingdom
Lisinopril
   Nationwide Children's Hospital
      2009   -   NCT01982695   United States
Lonafarnib
   Eiger BioPharmaceuticals
      2020   -   NCT03895528   -
   The Children's Hospital Zhejiang University School of Medicine
      2021   -   ChiCTR2100050052   China
Losartan
   Nationwide Children's Hospital
      2009   -   NCT01982695   United States
Losmapimod
   Fulcrum Therapeutics
      2022   Phase 3   NCT05397470   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000389-16-FR   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000389-16-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000389-16-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2020   Phase 2   NCT04264442   Canada;France;Germany;Spain;United States
      2019   Phase 2   NCT04004000   Netherlands
      2019   Phase 2   NCT04003974   Canada;France;Germany;Spain;United States
      -   Phase 3   EUCTR2022-000389-16-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   Fulcrum Therapeutics, Inc.
      2022   Phase 3   EUCTR2022-000389-16-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001181-15-FR   France;Germany;Spain;United States
      2019   Phase 2   EUCTR2019-001181-15-ES   France;Germany;Spain;United States
Lucen
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2020   Phase 2   EUCTR2019-004426-24-IT   Italy
Magnesio
   SAREPTA THERAPEUTICS, INC.
      2022   Phase 2   EUCTR2019-000601-77-IT   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
Magnesium oxide
   SAREPTA THERAPEUTICS, INC.
      2022   Phase 2   EUCTR2019-000601-77-IT   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
Mannitol
   Toda Tatsushi
      2021   Phase 1   JPRN-jRCT2031210252   -
Manual muscle testing
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
Mcgill pain questionnaire
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
Metabolic profile
   Monica Levy Andersen
      2013   -   NCT01921374   Brazil
Metformin
   University Hospital, Basel, Switzerland
      2013   Phase 3   NCT01995032   Switzerland
      2012   Phase 1   NCT02516085   -
Metformin 500MG
   Centre d'Etude des Cellules Souches (CECS)
      2013   Phase 2   EUCTR2013-001732-21-FR   France
Metformin and metformin & L-citrulline
   University Hospital, Basel, Switzerland
      2013   Phase 2   NCT02018731   Switzerland
Metformina - 500 30 compresse 500 MG
   DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
      2019   Phase 3   EUCTR2018-000692-32-IT   Italy
Methylphenidate
   Laval University
      2008   Phase 2/Phase 3   NCT01421992   Canada
Metohexal® succ ® 23,75 MG retardtabletten
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany
Metohexal® succ ® 47,5 MG retardtabletten
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany
Metohexal® succ ® 95 MG retardtabletten
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany
Metoprolol
   West China Second University Hospital, Sichuan University
      2020   Phase 4   ChiCTR2000032525   China
Metoprolol succinate
   Friedrich- Alexander- Universität Erlangen Nürnberg
      -   -   EUCTR2009-009871-36-DE   Germany
   Medical University of Gdansk
      2021   Phase 3   EUCTR2020-004901-29-PL   Poland
Mexiletine
   Lupin Ltd.
      2021   Phase 3   NCT04624750   France
      2020   -   NCT04616807   France;Germany;United Kingdom
   University of Rochester
      2011   Phase 2   NCT01406873   United States
Mexiletine 167 MG
   Lupin Ltd.
      2021   Phase 3   NCT04700046   -
Mexiletine granules FOR prolonged-release oral suspension
   Lupin Ltd.
      2025   Phase 3   NCT06549400   -
      2024   Phase 3   NCT06523400   -
MNK-1411
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
   Mallinckrodt ARD Inc.
      2018   Phase 2   EUCTR2017-004139-35-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004139-35-BG   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004139-35-BE   Argentina;Belgium;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States
Monocytes and megacaryocytes culture and RNA extraction
   Assistance Publique - Hôpitaux de Paris
      2018   -   NCT03424460   France
Motor function scales
   Hospital Universitari Vall d'Hebron Research Institute
      2021   -   NCT06924125   Spain
Motor milestone assessments
   Hospital Universitari Vall d'Hebron Research Institute
      2021   -   NCT06924125   Spain
Moxifloxacin hydrochloride
   Italfarmaco
      2021   Phase 1   NCT04821063   Canada
MULT-ingredient supplement
   McMaster University
      2024   Phase 3   NCT05848830   Canada
Muscle elastography
   Hospital Universitari Vall d'Hebron Research Institute
      2021   -   NCT06924125   Spain
Muscle ultrasound
   Hospital Universitari Vall d'Hebron Research Institute
      2021   -   NCT06924125   Spain
MYO-029
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2005   Phase 2   EUCTR2004-000622-67-GB   United Kingdom
   Wyeth is now a wholly owned subsidiary of Pfizer
      2005   Phase 1/Phase 2   NCT00104078   United States
Myoblast autologous graft
   University Hospital, Caen
      2019   Phase 2/Phase 3   NCT02878694   France
Myoblast transplantation
   CHU de Quebec-Universite Laval
      2014   Phase 1/Phase 2   NCT02196467   Canada
Myoblastes autologues
   CHU CAEN
      2019   Phase 2   EUCTR2015-001192-48-FR   France
Myodm
   Myogem Health Company, S.L.
      2020   -   NCT04634682   Spain
Myopaxon
   Masonic Cancer Center, University of Minnesota
      2025   Phase 1   NCT06692426   United States
Myotonia behaviour scale
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
N(4,5BIS methanesulfonyl2methylbenzoyl) guanidine hydrochloride monohydrate
   EspeRare
      2015   Phase 1   EUCTR2015-002530-50-ES   France;Italy;Spain;Switzerland;United Kingdom
N-(4,5-BIS methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate
   EspeRare
      2015   Phase 1   EUCTR2015-002530-50-GB   France;Italy;Spain;Switzerland;United Kingdom
      2015   Phase 1   EUCTR2015-002530-50-FR   France;Italy;Spain;Switzerland;United Kingdom
Nebivolol
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01648634   France
Needle biopsy OF THE vastus lateralis muscle
   University Hospital, Montpellier
      2010   -   NCT01596803   France
NON invasive prenatal diagnosis
   University Hospital, Montpellier
      2020   -   NCT04698551   France
NPC-14
   Kobe University
      2013   Phase 2   NCT01918384   Japan
NS-050/NCNP-03
   NS Pharma, Inc.
      2024   Phase 1/Phase 2   NCT06053814   Japan;United States
NS-065/NCNP-01
   NS Pharma, Inc
      2021   Phase 3   EUCTR2021-000122-10-IT   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003653-30-IT   China;Italy;Russian Federation;Spain;Turkey;United States
      2020   Phase 3   EUCTR2019-002076-13-IT   Australia;Belgium;Brazil;Canada;Chile;France;Greece;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   NS Pharma, Inc.
      2022   Phase 3   EUCTR2021-000122-10-NO   Australia;Canada;Chile;China;Czech Republic;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000122-10-NL   Australia;Canada;Chile;China;Czech Republic;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000122-10-GR   Australia;Canada;Chile;China;Czech Republic;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000122-10-ES   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003653-30-ES   China;Italy;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2019-002076-13-NO   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002076-13-NL   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002076-13-GR   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002076-13-GB   Australia;Belgium;Brazil;Canada;Chile;France;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-002076-13-ES   Australia;Belgium;Brazil;Canada;Chile;France;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 2   NCT03167255   Canada;United States
      2016   Phase 2   NCT02740972   Canada;United States
      -   Phase 3   EUCTR2021-000122-10-CZ   Australia;Canada;Chile;China;Czech Republic;Czechia;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2019-002076-13-SE   Australia;Belgium;Brazil;Canada;Chile;France;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   National Center of Neurology and Psychiatry, Japan
      2013   Phase 1   NCT02081625   Japan
   Nippon Shinyaku Co., Ltd.
      2020   Phase 3   JPRN-jRCT2080224893   Asia except Japan;Europe;Japan;North America;Oceania;South America
NS-089/NCNP-02
   NS Pharma, Inc.
      2024   Phase 2   NCT05996003   United States
   National Center of Neurology and Psychiatry, Japan
      2019   Phase 1/Phase 2   NCT04129294   Japan
   Nippon Shinyaku Co., Ltd.
      2021   Phase 2   NCT05135663   Japan
Nébivolol
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 3   EUCTR2010-020047-12-FR   France
Oligomero morfolino fosforodiamidato PER skipping dell’esone 45
   SAREPTA THERAPEUTICS, INC.
      2017   Phase 3   EUCTR2015-002069-52-IT   Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom
Oligomero morfolino fosforodiamidato PER skipping dell’esone 53
   SAREPTA THERAPEUTICS, INC.
      2017   Phase 3   EUCTR2015-002069-52-IT   Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom
Omigapil
   Santhera Pharmaceuticals
      2014   Phase 1   NCT01805024   United States
Oromotor function and nutrition
   Hospital Universitari Vall d'Hebron Research Institute
      2021   -   NCT06924125   Spain
Oxatomide
   Cooperative International Neuromuscular Research Group
      2002   Phase 2   NCT00033813   United States
P-188 NF
   Phrixus Pharmaceuticals, Inc.
      2018   Phase 2   NCT03558958   United States
Pamrevlumab
   FIBROGEN
      2021   Phase 3   EUCTR2020-000699-39-IT   Australia;Austria;Belgium;Canada;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000698-26-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
   FibroGen
      2020   Phase 3   NCT04632940   Australia;Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   NCT04371666   Australia;Austria;Belgium;Canada;China;Czechia;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2016   Phase 2   NCT02606136   United States
   FibroGen, Inc.
      2023   Phase 3   EUCTR2020-000698-26-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-000698-26-BE   Austria;Belgium;China;Czech Republic;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000699-39-NL   Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;United States
      2021   Phase 3   EUCTR2020-000699-39-FR   Australia;Austria;Belgium;Canada;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000699-39-ES   Australia;Austria;Belgium;Canada;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000699-39-BE   Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;United States
      2021   Phase 3   EUCTR2020-000699-39-AT   Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;United States
      2021   Phase 3   EUCTR2020-000698-26-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000698-26-AT   Austria;Belgium;China;Czech Republic;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000698-26-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000698-26-ES   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000698-26-CZ   Austria;Belgium;China;Czech Republic;Czechia;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
PB1046 injection
   PhaseBio Pharmaceuticals Inc.
      2016   Phase 2   NCT02808585   United States
Pemirolast
   Cardoz AB
      2011   -   EUCTR2011-004667-76-SE   Sweden
Pending
   Acceleron Pharma Inc.
      2019   Phase 2   EUCTR2019-000305-79-ES   Canada;Spain;United States
      2018   Phase 2   EUCTR2016-003257-15-ES   Canada;Spain;United States
   Summit (Oxford) Limited
      2016   Phase 2   EUCTR2015-004333-27-GB   United Kingdom;United States
Pentoxifylline
   Cooperative International Neuromuscular Research Group
      2005   Phase 1/Phase 2   NCT00243789   Argentina;Australia;Canada;Israel;Italy;United States
      2002   Phase 1/Phase 2   NCT00102453   United States
Peptide-conjugated phosphorodiamidate morpholino oligomer FOR exon 51 skipping
   Sarepta Therapeutics, Inc.
      2021   Phase 2   EUCTR2019-000601-77-DE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000601-77-NL   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000601-77-ES   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000601-77-IE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000601-77-GB   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000601-77-BE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2020-004803-15-Outside-EU/EEA   Canada;United States
Peptide-conjugated phosphorodiamide morpholino oligomer FOR exon 51 skipping
   SAREPTA THERAPEUTICS, INC.
      2022   Phase 2   EUCTR2019-000601-77-IT   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
Perindopril
   West China Second University Hospital, Sichuan University
      2020   Phase 4   ChiCTR2000032525   China
Perindopril 2MG tablets
   Newcastle upon Tyne Hospitals NHS Foundation Trust
      2009   Phase 3   EUCTR2007-005932-10-GB   United Kingdom
PF-06252616
   Pfizer
      2016   Phase 2   NCT02907619   Canada;Italy;Japan;United Kingdom;United States
      2014   Phase 2   NCT02310763   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States
   Pfizer Inc.
      2016   Phase 2   EUCTR2016-001615-21-GB   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2018   Phase 2   EUCTR2016-001615-21-BG   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001615-21-IT   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States
      2016   Phase 2   EUCTR2014-002072-92-PL   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States
      2016   Phase 2   EUCTR2014-002072-92-BG   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States
      2015   Phase 2   EUCTR2014-002072-92-IT   Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States
      2014   Phase 2   EUCTR2014-002072-92-GB   Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom;United States
PF-06939926
   PFIZER INC
      2020   Phase 3   EUCTR2019-002921-31-IT   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
   Pfizer
      2022   Phase 2   NCT05429372   Australia;United States
      2020   Phase 3   NCT04281485   Australia;Belgium;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 1   NCT03362502   United States
   Pfizer Inc.
      2022   Phase 3   EUCTR2019-002921-31-DE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-002921-31-FR   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-002921-31-BE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002921-31-GB   Belgium;Canada;China;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States
PGN-EDO51
   PepGen Inc
      2024   Phase 2   NCT06079736   Canada
PGN-edodm1
   PepGen Inc
      2024   Phase 2   NCT06667453   Canada
PGN-edodm1 FOR infusion
   PepGen Inc
      2023   Phase 1   NCT06204809   Canada;United Kingdom;United States
Phase 1, SQY51
   Sqy Therapeutics
      2023   Phase 1/Phase 2   NCT05753462   France
Phosphorodiamidate morpholino oligomer
   Imperial College, London
      2007   Phase 1;Phase 2   EUCTR2006-003833-33-GB   United Kingdom
Phosphorodiamidate morpholino oligomer FOR exon 45 skipping
   SAREPTA THERAPEUTICS, INC.
      2018   Phase 3   EUCTR2017-004625-32-IT   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
   Sarepta Therapeutics, Inc.
      2022   Phase 3   EUCTR2015-002069-52-NL   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-004625-32-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-004625-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2015-002069-52-NO   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004625-32-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004625-32-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2015-002069-52-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-GB   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-ES   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-SE   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-GB   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-ES   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2015-002069-52-FR   Belgium;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States
Phosphorodiamidate morpholino oligomer FOR exon 53 skipping
   SAREPTA THERAPEUTICS, INC.
      2018   Phase 3   EUCTR2017-004625-32-IT   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
   Sarepta Therapeutics, Inc.
      2022   Phase 3   EUCTR2015-002069-52-NL   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-004625-32-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-004625-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2015-002069-52-NO   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004625-32-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004625-32-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2015-002069-52-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-GB   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-ES   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-SE   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-GB   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-ES   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 1;Phase 2   EUCTR2014-002008-25-FR   France;Italy;United Kingdom
      2014   Phase 1;Phase 2   EUCTR2014-002008-25-IT   France;Italy;United Kingdom
      2014   Phase 1;Phase 2   EUCTR2014-002008-25-GB   France;Italy;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2015-002069-52-FR   Belgium;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States
Pitolisant oral tablet
   Harmony Biosciences, LLC
      2021   Phase 2   NCT04886518   Canada;United States
Plasmapheresis
   Sarepta Therapeutics, Inc.
      2024   Phase 1   NCT06597656   United States
PRD2175434
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom
Prednisolone
   Anne M. Connolly
      2021   Phase 4   NCT05412394   United States
   Ishigaki Keiko
      2023   Phase 2   JPRN-jRCT2031230210   -
   Ishigaki Keiko
      2023   Phase 2   JPRN-jRCT2031230211   -
   Kevin Flanigan
      2018   Phase 1   NCT03777319   United States
   Washington University School of Medicine
      2014   Phase 2   NCT02167217   United States
Prednison
   Universitätsklinik Freiburg
      2005   Phase 2;Phase 3   EUCTR2005-000663-26-AT   Austria
Prednisone
   AZIENDA OSPEDALIERA DI PADOVA
      2013   -   EUCTR2010-023744-33-IT   Canada;Italy;United Kingdom;United States
   Ann & Robert H Lurie Children's Hospital of Chicago
      2014   Phase 2   NCT02036463   United States
   Cooperative International Neuromuscular Research Group
      2007   Phase 3   NCT00308113   Australia;Puerto Rico;United States
      2004   Phase 3   NCT00110669   India;United States
   F. HOFFMANN - LA ROCHE LTD.
      2022   Phase 2   EUCTR2022-000691-19-IT   Belgium;France;Germany;Italy;Spain;United Kingdom
   National Center for Research Resources (NCRR)
      1995   Phase 3   NCT00004646   -
   Northwestern University
      2019   Phase 2   NCT04054375   United States
   ReveraGen BioPharma, Inc
      2019   Phase 2   EUCTR2017-002704-27-GR   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom
   ReveraGen BioPharma, Inc.
      2019   Phase 2   EUCTR2017-002704-27-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002704-27-ES   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002704-27-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002704-27-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   NCT03439670   Australia;Belgium;Canada;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002704-27-SE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002704-27-GB   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   SAREPTA THERAPEUTICS, INC.
      2023   Phase 3   EUCTR2020-002372-13-IT   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003374-91-IT   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
Prednisone 5 MG tablets
   University of Rochester
      2012   -   EUCTR2010-023744-33-GB   Canada;Germany;Italy;United Kingdom;United States
Prednisone plus exercise
   University of Florida
      2020   Phase 2   NCT04322357   United States
Pressure pain threshold
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
Primidone
   The first hospital of Yichang
      2022   Phase 2   ChiCTR2200063970   China
PRO044
   BioMarin Nederland B.V.
      2014   Phase 2   EUCTR2013-003605-26-SE   Belgium;Netherlands;Sweden
   PROSENSA THERAPEUTICS BV
      2010   -   EUCTR2009-013762-63-IT   Belgium;Italy;Netherlands;Sweden
   Prosensa Therapeutics B.V
      2010   -   EUCTR2009-013762-63-SE   Belgium;Italy;Netherlands;Sweden
      2010   -   EUCTR2009-013762-63-NL   Belgium;Italy;Netherlands;Sweden
      2009   Phase 1;Phase 2   EUCTR2009-013762-63-BE   Belgium;Italy;Netherlands;Sweden
   Prosensa Therapeutics B.V.
      2015   Phase 2   EUCTR2013-003605-26-NL   Belgium;Netherlands;Sweden
      2015   Phase 2   EUCTR2013-003605-26-BE   Belgium;Netherlands;Sweden
      2014   Phase 2   EUCTR2013-003605-26-IT   Belgium;Italy;Netherlands;Sweden
PRO044 IV
   BioMarin Pharmaceutical
      2009   Phase 1/Phase 2   NCT01037309   Belgium;Italy;Netherlands;Sweden
PRO044 IV 6 MG/KG
   BioMarin Pharmaceutical
      2014   Phase 2   NCT02329769   Belgium;Italy;Netherlands;Sweden
PRO044 IV 9 MG/KG
   BioMarin Pharmaceutical
      2014   Phase 2   NCT02329769   Belgium;Italy;Netherlands;Sweden
PRO044 SC
   BioMarin Pharmaceutical
      2009   Phase 1/Phase 2   NCT01037309   Belgium;Italy;Netherlands;Sweden
PRO044 SC 6 MG/KG
   BioMarin Pharmaceutical
      2014   Phase 2   NCT02329769   Belgium;Italy;Netherlands;Sweden
PRO045
   BioMarin Nederland B.V.
      2012   Phase 1;Phase 2   EUCTR2011-005040-10-BE   Belgium;Italy;United Kingdom
   Prosensa Therapeutics BV
      2013   Phase 1;Phase 2   EUCTR2011-005040-10-IT   Belgium;Italy;United Kingdom
      -   Phase 1;Phase 2   EUCTR2011-005040-10-FR   Belgium;France;Italy;United Kingdom
PRO045, 0.15 MG/KG/week
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom
PRO045, 1.0 MG/KG/week
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom
PRO045, 3.0 MG/KG/week
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom
PRO045, 6.0 MG/KG/week
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom
PRO045, 9.0 MG/KG/week
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom
PRO045, selected dose
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01826474   Belgium;France;Italy;Netherlands;United Kingdom
PRO051
   BioMarin Pharmaceutical Inc.
      2016   Phase 3   EUCTR2015-001955-54-DE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay
      2016   Phase 3   EUCTR2015-001955-54-BE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay
      2015   Phase 3   EUCTR2015-001955-54-ES   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;Uruguay
   Prosensa Holding B.V.
      2008   -   EUCTR2007-004819-54-NL   Belgium;Netherlands;Sweden
   Prosensa Therapeutics BV
      2008   Phase 1;Phase 2   EUCTR2007-004819-54-SE   Belgium;Netherlands;Sweden
      2008   Phase 1;Phase 2   EUCTR2007-004819-54-BE   Belgium;Netherlands;Sweden
PRO053
   Prosensa Therapeutics BV
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2011-005042-35-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States
Protein-carbohydrate supplementation
   Grete Andersen, MD
      2012   -   NCT01618331   Denmark
Provigil - 100 MG compresse 30 compresse
   FONDAZIONE SERENA ONLUS
      2016   Phase 3   EUCTR2016-000601-36-IT   Italy
PS188
   BIOMARIN PHARMACEUTICAL INC.
      -   Phase 2   EUCTR2015-003681-87-IT   Belgium;Italy;Netherlands;Sweden;United States
   BioMarin Nederland B.V.
      2014   Phase 2   EUCTR2013-003605-26-SE   Belgium;Netherlands;Sweden
   BioMarin Pharmaceutical Inc.
      2016   Phase 2   EUCTR2015-003681-87-BE   Belgium;Italy;Netherlands;Sweden;United States
   Prosensa Therapeutics B.V.
      2015   Phase 2   EUCTR2013-003605-26-NL   Belgium;Netherlands;Sweden
      2015   Phase 2   EUCTR2013-003605-26-BE   Belgium;Netherlands;Sweden
      2014   Phase 2   EUCTR2013-003605-26-IT   Belgium;Italy;Netherlands;Sweden
PS220
   BioMarin Nederland B.V.
      2012   Phase 1;Phase 2   EUCTR2011-005040-10-BE   Belgium;Italy;United Kingdom
   BioMarin Pharmaceutical Inc.
      2013   Phase 1;Phase 2   EUCTR2011-005040-10-GB   Belgium;France;Italy;United Kingdom
   Prosensa Therapeutics BV
      2013   Phase 1;Phase 2   EUCTR2011-005040-10-IT   Belgium;Italy;United Kingdom
      -   Phase 1;Phase 2   EUCTR2011-005040-10-FR   Belgium;France;Italy;United Kingdom
PS524
   BioMarin Nederland B.V.
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States
   BioMarin Pharmaceutical Inc.
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States
   Prosensa Therapeutics BV
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States
      2013   Phase 1;Phase 2   EUCTR2011-005042-35-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2011-005042-35-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Turkey;United Kingdom;United States
PTC0161480, PTC124 compound 1A, RPS2505, PTC-C124, 291844
   PTC Therapeutics Inc
      2010   -   EUCTR2009-013169-24-GB   United Kingdom
   PTC Therapeutics, Inc.
      2009   -   EUCTR2008-007648-32-SE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-007648-32-GB   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-007648-32-FR   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-007648-32-ES   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-007648-32-DE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-007648-32-BE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2007-005478-29-GB   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-005478-29-SE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2008   Phase 2   EUCTR2007-005478-29-FR   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2008   Phase 2   EUCTR2007-005478-29-ES   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-005478-29-DE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-005478-29-BE   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
PTC124
   PTC THERAPEUTICS, INC.
      2012   Phase 3   EUCTR2011-004853-18-IT   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-007648-32-IT   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-005478-29-IT   Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom
   PTC Therapeutics
      2005   Phase 2   NCT00264888   United States
   PTC Therapeutics (Medpace Japan K.K.. ; In-Country Caretaker for Clinical trials).
      2018   Phase 3   JPRN-jRCT2080224563   Asia except Japan;Europe;Japan;North America;Oceania;South America
   PTC Therapeutics, Inc
      2014   -   EUCTR2012-004527-20-PL   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004527-20-SE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   -   EUCTR2012-004527-20-IT   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004527-20-GB   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   -   EUCTR2012-004527-20-ES   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004527-20-DE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004527-20-CZ   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004527-20-BE   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004853-18-SE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2011-004853-18-FR   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2011-004853-18-ES   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2011-004853-18-BE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2012-004527-20-FR   Australia;Belgium;Brazil;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   PTC Therapeutics, Inc.
      2018   Phase 3   EUCTR2017-001223-49-BG   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States
      2016   Phase 3   EUCTR2013-005489-20-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005489-20-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005489-20-BG   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-SE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-005489-20-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Israel;Italy;Korea, Republic of;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004853-18-GB   Australia;Belgium;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2011-004853-18-DE   Australia;Belgium;Canada;Germany;Israel;Italy;Spain;Sweden;United Kingdom
      -   Phase 2   EUCTR2020-000980-21-Outside-EU/EEA   United States
      -   Phase 3   EUCTR2017-001223-49-PL   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States
Quantitative muscle testing
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
Quick motor function test
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
R-pact
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
RAAV1.CMV.hufollistatin344
   Nationwide Children's Hospital
      2012   Phase 1   NCT01519349   United States
RAAV1.CMV.hufollistin344
   Jerry R. Mendell
      2015   Phase 1/Phase 2   NCT02354781   United States
RAAV1.tmck.human-alpha-sarcoglycan- first cohort
   Nationwide Children's Hospital
      2008   Phase 1   NCT00494195   United States
RAAV1.tmck.human-alpha-sarcoglycan- second cohort
   Nationwide Children's Hospital
      2008   Phase 1   NCT00494195   United States
RAAV8-HMD1
   Genethon
      2020   Phase 1;Phase 2;Phase 3   EUCTR2020-002093-27-FR   France;Israel;United Kingdom;United States
RAAV9-CK8-H-µD5
   Solid Biosciences Inc.
      2019   Phase 1;Phase 2   EUCTR2017-002213-60-GB   United Kingdom;United States
RAAV9-hfkrpco_mir-208A
   Atamyo Therapeutics
      2022   Phase 1;Phase 2   EUCTR2021-004276-33-FR   Canada;Denmark;France;Germany;Norway;Sweden;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2021-004276-33-DK   Canada;Denmark;France;Germany;Norway;Sweden;United Kingdom;United States
Raavrh74.MCK.galgt2
   Kevin Flanigan
      2017   Phase 1/Phase 2   NCT03333590   United States
      2016   Phase 1/Phase 2   NCT02704325   United States
Raavrh74.MCK.micro-dystrophin
   Jerry R. Mendell
      2015   Phase 1   NCT02376816   United States
Ramipril
   Catholic University, Italy
      2008   Phase 4   NCT00819845   Italy
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2008   -   EUCTR2008-007236-18-IT   Italy
Ranolazine
   Ohio State University
      2014   Phase 1   NCT02251457   United States
Raxone
   SANTHERA PHARMACEUTICALS
      2018   Phase 3   EUCTR2017-004279-30-IT   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
   Santhera Pharmaceuticals (Switzerland) Limited
      2020   Phase 3   EUCTR2017-004279-30-NL   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2016-000602-10-BG   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004279-30-AT   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004279-30-GB   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004279-30-ES   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004279-30-BE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2016-000602-10-HU   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000602-10-NL   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-GB   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-FR   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-ES   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-DE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-BE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000602-10-AT   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2017-004279-30-SE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2017-004279-30-FR   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2017-004279-30-DE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-000602-10-SE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-000602-10-IE   Austria;Belgium;Bulgaria;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Raxone - 150 MG- compresse rivestite CON FILM- USO orale- flacone (hdpe)- 180 compresse
   SANTHERA PHARMACEUTICALS
      2016   Phase 3   EUCTR2016-000602-10-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Recombinant human ANTI-GDF-8 antibody
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2005   Phase 2   EUCTR2004-000622-67-GB   United Kingdom
Regimen selection phase group 2
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01957059   Belgium;France;Italy;Netherlands;United Kingdom
Regimen selection phase group 3
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01957059   Belgium;France;Italy;Netherlands;United Kingdom
Regular exercise
   Grete Andersen, MD
      2012   -   NCT01618331   Denmark
Renadirsen
   DAIICHI SANKYO Co.,Ltd.
      2020   Phase 2   JPRN-jRCT2080225225   Japan
Resveratrol
   Sapporo Medical University
      2014   -   JPRN-UMIN000014836   Japan
Revatio
   Rigshospitalet
      2011   -   EUCTR2010-024659-10-DK   Denmark
RGX-202
   REGENXBIO Inc.
      2023   Phase 2/Phase 3   NCT05693142   Canada;United States
Rhigf-I/rhigfbp-3
   Insmed Incorporated
      2007   Phase 2   NCT00577577   United States
Ribitol
   ML Bio Solutions, Inc.
      2023   Phase 3   NCT05775848   Australia;Denmark;Germany;Italy;Netherlands;Norway;United Kingdom;United States
Rimeporide
   ESPERARE FOUNDATION
      2017   Phase 1   EUCTR2015-002530-50-IT   France;Italy;Spain;United Kingdom
   EspeRare
      2015   Phase 1   EUCTR2015-002530-50-GB   France;Italy;Spain;Switzerland;United Kingdom
      2015   Phase 1   EUCTR2015-002530-50-FR   France;Italy;Spain;Switzerland;United Kingdom
      2015   Phase 1   EUCTR2015-002530-50-ES   France;Italy;Spain;Switzerland;United Kingdom
   EspeRare Foundation
      2016   Phase 1   NCT02710591   France;Italy;Spain;United Kingdom
Risedronate sodium
   The Central Remedial Clinic and The Children's University Hospital
      2010   Phase 2   EUCTR2009-017649-67-IE   Ireland
RO720-4239/F01-01
   F.Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2021-006255-34-DK   Denmark;Italy;United Kingdom;United States
RO7204239
   F.Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2021-006255-34-DK   Denmark;Italy;United Kingdom;United States
   Hoffmann-La Roche
      2023   Phase 2   NCT05548556   Denmark;Italy;United Kingdom;United States
RO7239361
   F. Hoffmann-La Roche Ltd
      2017   Phase 3   EUCTR2016-001654-18-SE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-NL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001654-18-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Hoffmann-La Roche
      2017   Phase 2/Phase 3   NCT03039686   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2015   Phase 1/Phase 2   NCT02515669   Canada;United States
RO7494222 (SRP-9001)
   F. Hoffmann-La Roche Ltd
      2024   Phase 2   EUCTR2022-000691-19-BE   Belgium;France;Germany;Italy;Spain;United Kingdom
Saline injection
   CHU de Quebec-Universite Laval
      2014   Phase 1/Phase 2   NCT02196467   Canada
Sandimmun optoral
   Universitätsklinik Freiburg
      2005   Phase 2;Phase 3   EUCTR2005-000663-26-AT   Austria
SAR446268
   Sanofi
      2025   Phase 1/Phase 2   NCT06844214   -
SAT-3247
   Satellos Bioscience, Inc.
      2025   Phase 2   NCT06867107   Australia
      2024   Early Phase 1   NCT06565208   Australia
Satralizumab
   Hoffmann-La Roche
      2025   Phase 2   NCT06450639   Italy;Poland;Spain;United States
Satralizumab prefilled syringe
   Centre Hospitalier Universitaire de Nice
      2024   Phase 2   NCT06222827   Canada;France
Scaav9.U7.acca
   Megan Waldrop
      2020   Phase 1/Phase 2   NCT04240314   United States
Scale FOR assessment and rating OF ataxia
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
Sevasemten
   Edgewise Therapeutics, Inc.
      2023   Phase 2   NCT06066580   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2021   Phase 1   NCT05160415   United States
Sevasemten 10 MG
   Edgewise Therapeutics, Inc.
      2022   Phase 2   NCT05291091   Australia;Belgium;Denmark;France;Germany;Israel;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States
Sevasemten 12.5 MG
   Edgewise Therapeutics, Inc.
      2022   Phase 2   NCT05291091   Australia;Belgium;Denmark;France;Germany;Israel;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States
Sevasemten 5 MG
   Edgewise Therapeutics, Inc.
      2022   Phase 2   NCT05291091   Australia;Belgium;Denmark;France;Germany;Israel;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States
Sevasemten dose 1
   Edgewise Therapeutics, Inc.
      2024   Phase 2   NCT06100887   United States
      2022   Phase 2   NCT05540860   United States
Sevasemten dose 2
   Edgewise Therapeutics, Inc.
      2024   Phase 2   NCT06100887   United States
      2022   Phase 2   NCT05540860   United States
Sevasemten dose 3
   Edgewise Therapeutics, Inc.
      2024   Phase 2   NCT06100887   United States
      2022   Phase 2   NCT05540860   United States
Sevasemten dose 4
   Edgewise Therapeutics, Inc.
      2022   Phase 2   NCT05540860   United States
Sevasemten dose 5
   Edgewise Therapeutics, Inc.
      2022   Phase 2   NCT05540860   United States
SGT-001
   Solid Biosciences Inc.
      2019   Phase 1;Phase 2   EUCTR2017-002213-60-GB   United Kingdom;United States
      2017   Phase 1/Phase 2   NCT03368742   United States
SGT-003
   Solid Biosciences Inc.
      2024   Phase 1/Phase 2   NCT06138639   Canada;United States
Sildenafil
   Cedars-Sinai Medical Center
      2011   Early Phase 1   NCT01359670   United States
   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      2010   Phase 2   NCT01168908   United States
   Rigshospitalet
      2011   -   EUCTR2010-024659-10-DK   Denmark
   Rigshospitalet, Denmark
      2011   Phase 2   NCT01350154   Denmark
SIX minute walking test
   Prof. Dr. Benedikt Schoser
      2018   -   NCT03603171   Germany
Sleep parameters
   Monica Levy Andersen
      2013   -   NCT01921374   Brazil
SMT C1100
   Summit (Oxford) Limited
      2016   Phase 2   EUCTR2015-004333-27-GB   United Kingdom;United States
      2014   Phase 1   EUCTR2014-003100-78-GB   United Kingdom
   Summit Corporation Plc.
      2013   Phase 1   NCT02056808   United Kingdom
   Summit Corporation plc
      2013   Phase 1   EUCTR2013-002115-99-GB   United Kingdom
   Summit Therapeutics
      2015   Phase 1   NCT02383511   United Kingdom
SMT C1100 (F5
   Summit (Oxford) Limited
      2015   Phase 1   EUCTR2015-001967-38-GB   United Kingdom
SMT C1100 (F6
   Summit (Oxford) Limited
      2015   Phase 1   EUCTR2015-001967-38-GB   United Kingdom
SNT-MC17
   SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD
      2012   -   EUCTR2009-012037-30-IT   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United States
   Santhera Pharmaceuticals (Switzerland) Limited
      2012   -   EUCTR2009-012037-30-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2010   -   EUCTR2009-012037-30-SE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2010   Phase 3   EUCTR2009-012037-30-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2010   -   EUCTR2009-012037-30-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden
      2010   -   EUCTR2009-012037-30-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2009   -   EUCTR2009-012037-30-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
      2009   Phase 3   EUCTR2009-012037-30-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United States
   Santhera Pharmaceuticals (Switzerland) Ltd
      2008   -   EUCTR2007-007752-34-BE   Belgium
Sodium nitrate
   Cedars-Sinai Medical Center
      2015   Phase 1   NCT02434627   United States
      2013   Phase 1   NCT02847975   United States
Sodium nitrate - double dose
   Cedars-Sinai Medical Center
      2013   Phase 2/Phase 3   NCT02147639   United States
Somatokine/iplex
   University of Rochester
      2005   Phase 1/Phase 2   NCT00233519   United States
Somatropin
   University of Rochester
      2017   Phase 1   NCT03123913   United States
Spironolactone
   Kevin Flanigan
      2018   Phase 1   NCT03777319   United States
   Ohio State University
      2015   Phase 3   NCT02354352   United States
SRD-001
   Sardocor Corp.
      2024   Phase 1   NCT06224660   United States
SRP-4045
   SAREPTA THERAPEUTICS, INC.
      2018   Phase 3   EUCTR2017-004625-32-IT   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-IT   Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom
   Sarepta Therapeutics, Inc.
      2022   Phase 3   EUCTR2015-002069-52-NL   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-004625-32-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-004625-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2015-002069-52-NO   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004625-32-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004625-32-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2015-002069-52-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-GB   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-ES   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-SE   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-GB   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-ES   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   NCT02500381   Argentina;Australia;Belgium;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States
      2015   Phase 1   NCT02530905   United States
      -   Phase 3   EUCTR2017-004625-32-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2015-002069-52-FR   Belgium;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States
SRP-4053
   SAREPTA THERAPEUTICS, INC.
      2018   Phase 3   EUCTR2017-004625-32-IT   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-IT   Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom
   Sarepta Therapeutics, Inc.
      2022   Phase 3   EUCTR2015-002069-52-NL   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-004625-32-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-004625-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2015-002069-52-NO   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2015-002069-52-IE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004625-32-FR   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004625-32-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2015-002069-52-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2015-002069-52-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-GB   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-ES   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004625-32-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Ireland;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2015-002069-52-BG   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-SE   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-GB   Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-ES   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2015-002069-52-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   NCT02500381   Argentina;Australia;Belgium;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States
      2016   Phase 1;Phase 2   EUCTR2014-002008-25-FR   France;Italy;United Kingdom
      2015   Phase 1/Phase 2   NCT02310906   France;Italy;United Kingdom;United States
      2014   Phase 1;Phase 2   EUCTR2014-002008-25-IT   France;Italy;United Kingdom
      2014   Phase 1;Phase 2   EUCTR2014-002008-25-GB   France;Italy;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2017-004625-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2015-002069-52-FR   Belgium;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States
SRP-5051
   SAREPTA THERAPEUTICS, INC.
      2022   Phase 2   EUCTR2019-000601-77-IT   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
   Sarepta Therapeutics, Inc.
      2021   Phase 2   EUCTR2019-000601-77-DE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000601-77-NL   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000601-77-ES   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000601-77-IE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000601-77-GB   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000601-77-BE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 1/Phase 2   NCT03675126   Canada;United States
      -   Phase 1;Phase 2   EUCTR2020-004803-15-Outside-EU/EEA   Canada;United States
SRP-6004
   Sarepta Therapeutics, Inc.
      2023   Phase 1   NCT05906251   United States
SRP-9001
   F. HOFFMANN - LA ROCHE LTD.
      2022   Phase 2   EUCTR2022-000691-19-IT   Belgium;France;Germany;Italy;Spain;United Kingdom
   F. Hoffmann-La Roche Ltd
      2023   Phase 2   EUCTR2022-000691-19-FR   Belgium;France;Germany;Italy;Spain;United Kingdom
      2023   Phase 2   EUCTR2022-000691-19-DE   Belgium;France;Germany;Italy;Spain;United Kingdom
   SAREPTA THERAPEUTICS, INC.
      2023   Phase 3   EUCTR2020-002372-13-IT   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003374-91-IT   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
   Sarepta Therapeutics, Inc
      2023   Phase 1   EUCTR2022-003407-15-ES   Spain
   Sarepta Therapeutics, Inc.
      2023   Phase 3   EUCTR2020-002372-13-FR   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2020-002372-13-BE   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002372-13-SE   Australia;Belgium;France;Germany;Israel;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003374-91-FR   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003374-91-ES   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003374-91-BE   Belgium;France;Germany;Hong Kong;Italy;Japan;Spain;Taiwan;United Kingdom;United States
SRP-9003
   Sarepta Therapeutics, Inc.
      2024   Phase 3   NCT06246513   United Kingdom;United States
      2022   Phase 1   NCT05876780   United States
      2018   Phase 1/Phase 2   NCT03652259   United States
SRP-9004
   Sarepta Therapeutics, Inc.
      2025   Phase 1   NCT06747273   United States
      2015   Phase 1/Phase 2   NCT01976091   United States
SRP-9005
   Sarepta Therapeutics, Inc.
      2025   Phase 3   NCT06952686   -
Standard steroid treatment
   Children's Hospital Medical Center, Cincinnati
      2010   Phase 1/Phase 2   NCT01207908   United States
Stem cell
   Chaitanya Hospital, Pune
      2014   Phase 1/Phase 2   NCT01834066   India
   Neurogen Brain and Spine Institute
      2010   Phase 1   NCT02245711   India
      2009   Phase 1   NCT02241928   India
      2009   Phase 1   NCT02241434   India
Stem cells
   Stem Cells Arabia
      2015   Phase 1/Phase 2   NCT03067831   Jordan
Sunphenon egcg
   Charite Universitätsmedizin Berlin
      2010   Phase 2   EUCTR2009-016482-28-DE   Germany
Sustanon 250
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom
Suvodirsen
   Wave Life Sciences Ltd.
      2019   Phase 2/Phase 3   NCT03907072   Belgium;Canada;Czechia;France;Italy;Sweden;United Kingdom;United States
   Wave Life Sciences UK Limited
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-SE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-IT   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2018-004009-22-PL   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2018-004009-22-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2018-004009-22-FR   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2018-004009-22-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
Synacthen ampoules 250 MCG
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
Synacthen ampoules 250 microgrammi
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
Tacrolimus
   FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
      2011   -   EUCTR2011-000176-33-IT   Italy
   Masonic Cancer Center, University of Minnesota
      2025   Phase 1   NCT06692426   United States
Tadalafil
   Cedars-Sinai Medical Center
      2012   -   NCT03076814   -
      2012   Phase 4   NCT02207283   -
      2011   Early Phase 1   NCT01359670   United States
      2010   Phase 4   NCT01070511   United States
   Eli Lilly Japan K.K.
      2014   Phase 3   JPRN-jRCT2080222487   -
   Eli Lilly and Company
      2013   Phase 3   NCT01865084   Argentina;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Puerto Rico;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-NL   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-IT   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001194-25-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001194-25-DE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2013   -   EUCTR2013-001194-25-BE   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Lilly S.A.
      2013   Phase 3   EUCTR2013-001194-25-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
   University of Florida
      2024   Phase 2   NCT06290713   United States
      2021   Phase 2/Phase 3   NCT05195775   United States
Tadalafil 20 MG
   Cedars-Sinai Medical Center
      2017   Early Phase 1   NCT02653833   United States
Tadalafil and sildenafil
   Cedars-Sinai Medical Center
      2012   Phase 1   NCT01580501   United States
Taking OF blood
   University Hospital, Montpellier
      2010   -   NCT01596803   France
Talfirastide
   Constant Therapeutics LLC
      2023   Phase 2   NCT06013839   Israel
Tamox
   University of Basel Children's Hospital, Division of Neuropediatrics
      2019   Phase 3   EUCTR2017-004554-42-ES   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom
Tamoxifen
   University Hospital, Basel, Switzerland
      2018   Phase 3   NCT03354039   France;Germany;Netherlands;Spain;Switzerland;United Kingdom
Tamoxifen 20MG hexal® filmtabletten
   University of Basel Children's Hospital, Division of Neuropediatrics
      2020   Phase 3   EUCTR2017-004554-42-FR   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004554-42-GB   Belgium;France;Germany;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2017-004554-42-DE   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004554-42-BE   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom
Tamoxifen citrate
   University of Basel Children's Hospital, Division of Neuropediatrics
      2020   Phase 3   EUCTR2017-004554-42-FR   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004554-42-NL   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom
      2019   Phase 3   EUCTR2017-004554-42-GB   Belgium;France;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2019   Phase 3   EUCTR2017-004554-42-ES   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004554-42-DE   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2017-004554-42-BE   Belgium;France;Germany;Netherlands;Spain;Switzerland;Turkey;United Kingdom
TAS-205
   Taiho Pharmaceutical Co., Ltd.
      2020   Phase 3   NCT04587908   Japan
      2016   Phase 2   NCT02752048   Japan
      2014   Phase 1   NCT02246478   Japan
Tehalose 30GR
   Bioblast Pharma Ltd.
      2015   Phase 3   NCT02328482   Canada
Temerit
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 3   EUCTR2010-020047-12-FR   France
Testosterone
   Newcastle-upon-Tyne Hospitals NHS Trust
      2015   -   NCT02571205   United Kingdom
Testosterone decanoate
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom
Testosterone enanthate
   University of Rochester
      2017   Phase 1   NCT03123913   United States
Testosterone isocaproate
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom
Testosterone phenylpropionate
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom
Testosterone propionate
   The Newcastle upon Tyne NHS Hospitals Foundation Trust
      2015   Phase 3   EUCTR2015-003195-68-GB   United Kingdom
Tetracosactide esacetato
   MALLINCKRODT ARD INC.
      2018   Phase 2   EUCTR2017-004139-35-IT   Bulgaria;Canada;Costa Rica;India;Ireland;Israel;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;United States
Tetracosactide hexaacetate
   Mallinckrodt ARD Inc.
      2018   Phase 2   EUCTR2017-004139-35-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004139-35-BG   Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004139-35-BE   Argentina;Belgium;Canada;Chile;Germany;Israel;Italy;Netherlands;Serbia;Spain;Turkey;United Kingdom;United States
Tideglusib
   AMO Pharma Limited
      2021   Phase 2/Phase 3   NCT05004129   Australia;Canada;New Zealand;United States
      2021   Phase 2/Phase 3   NCT03692312   Australia;Canada;New Zealand;United Kingdom;United States
      2016   Phase 2   NCT02858908   United Kingdom
   AMO Pharma Ltd
      2018   Phase 2;Phase 3   EUCTR2016-004623-23-GB   Canada;United Kingdom;United States
   AMO Pharma Ltd.
      2016   Phase 2   EUCTR2016-000067-16-GB   United Kingdom
TO BE determined
   Genethon
      2020   Phase 1;Phase 2;Phase 3   EUCTR2020-002093-27-FR   France;Israel;United Kingdom;United States
Tranilast
   Matsumura Tsuyoshi
      2024   Phase 2   JPRN-jRCT2051230201   -
      2018   -   JPRN-jRCTs031180038   -
   National Hospital Organization Toneyama National Hospital
      2018   -   JPRN-UMIN000031965   Japan
      2016   -   JPRN-UMIN000020580   Japan
Translarna
   PTC Therapeutics, Inc.
      -   Phase 2   EUCTR2020-000980-21-Outside-EU/EEA   United States
Translarna 1000 MG granules FOR oral suspension
   PTC Therapeutics, Inc.
      2018   Phase 3   EUCTR2017-001223-49-BG   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States
      -   Phase 3   EUCTR2017-001223-49-PL   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States
Translarna 125 MG granules FOR oral suspension
   PTC Therapeutics, Inc.
      2018   Phase 3   EUCTR2017-001223-49-BG   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States
      -   Phase 3   EUCTR2017-001223-49-PL   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States
Translarna 250 MG granules FOR oral suspension
   PTC Therapeutics, Inc.
      2018   Phase 3   EUCTR2017-001223-49-BG   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States
      -   Phase 3   EUCTR2017-001223-49-PL   Argentina;Australia;Brazil;Bulgaria;Canada;China;Hong Kong;India;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Thailand;Turkey;United States
Treatment phase group 4
   BioMarin Pharmaceutical
      2013   Phase 1/Phase 2   NCT01957059   Belgium;France;Italy;Netherlands;United Kingdom
Treatment taken
   Assistance Publique - Hôpitaux de Paris
      2024   Phase 3   NCT05532813   France
Trehalose
   Bioblast Pharma Ltd.
      2017   Phase 2   NCT04226924   Canada
Triatec
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2008   -   EUCTR2008-007236-18-IT   Italy
Triplet-primed PCR or LONG-read sequencing
   First Affiliated Hospital of Fujian Medical University
      2008   -   NCT06979024   China
Umbilical cord mesenchymal stem cell
   Acibadem University
      2013   Phase 1/Phase 2   NCT02285673   Turkey
Umbilical cord mesenchymal stem cells
   Allergy and Asthma Consultants, Wichita, Kansas
      2014   Phase 1   NCT02235844   United States
Vamarolone
   ReveraGen BioPharma Inc.
      2017   Phase 2   EUCTR2016-004263-38-SE   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004262-26-SE   Australia;Canada;Israel;Sweden;United Kingdom;United States
   ReveraGen BioPharma, Inc.
      2017   Phase 2   EUCTR2016-004462-26-GB   Australia;Canada;Israel;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004263-38-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004262-26-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States
Vamorolone
   Catalyst Pharmaceuticals, Inc.
      2024   -   NCT06564974   Puerto Rico;United States
   ReveraGen BioPharma Inc.
      2023   Phase 2   EUCTR2022-000844-31-IT   Italy;United States
      2018   Phase 2   EUCTR2017-003568-10-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2017-003568-10-SE   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004263-38-SE   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004262-26-SE   Australia;Canada;Israel;Sweden;United Kingdom;United States
   ReveraGen BioPharma, Inc
      2019   Phase 2   EUCTR2017-002704-27-GR   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom
   ReveraGen BioPharma, Inc.
      2022   Phase 2   NCT05166109   Italy;United States
      2019   Phase 2   EUCTR2017-002704-27-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002704-27-ES   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002704-27-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002704-27-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   NCT03439670   Australia;Belgium;Canada;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002704-27-SE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002704-27-GB   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004462-26-GB   Australia;Canada;Israel;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004263-38-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004262-26-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States
   Santhera Pharmaceuticals
      2022   Phase 2   NCT05185622   Canada
      2015   -   NCT03863119   Canada;Israel;United States
   Santhera Pharmaceuticals (Schweiz) AG
      -   Phase 2   EUCTR2025-000201-16-Outside-EU/EEA   Canada
Vamorolone 0.25 MG/DAY/DAY
   ReveraGen BioPharma, Inc.
      2017   Phase 2   NCT03038399   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2016   Phase 2   NCT02760277   Australia;Canada;Israel;Sweden;United Kingdom;United States
Vamorolone 0.25 MG/KG/DAY
   ReveraGen BioPharma, Inc.
      2016   Phase 2   NCT02760264   Australia;Canada;Israel;Sweden;United Kingdom;United States
Vamorolone 0.75 MG/DAY/DAY
   ReveraGen BioPharma, Inc.
      2017   Phase 2   NCT03038399   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2016   Phase 2   NCT02760277   Australia;Canada;Israel;Sweden;United Kingdom;United States
Vamorolone 0.75 MG/KG/DAY
   ReveraGen BioPharma, Inc.
      2016   Phase 2   NCT02760264   Australia;Canada;Israel;Sweden;United Kingdom;United States
Vamorolone 2.0 MG/DAY/DAY
   ReveraGen BioPharma, Inc.
      2017   Phase 2   NCT03038399   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2016   Phase 2   NCT02760277   Australia;Canada;Israel;Sweden;United Kingdom;United States
Vamorolone 2.0 MG/KG/DAY
   ReveraGen BioPharma, Inc.
      2016   Phase 2   NCT02760264   Australia;Canada;Israel;Sweden;United Kingdom;United States
Vamorolone 40 MG/ML oral suspension
   Santhera Pharmaceuticals
      2024   Phase 4   NCT06713135   Belgium;Czechia;Spain;United Kingdom
Vamorolone 6.0 MG/DAY/DAY
   ReveraGen BioPharma, Inc.
      2017   Phase 2   NCT03038399   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2016   Phase 2   NCT02760277   Australia;Canada;Israel;Sweden;United Kingdom;United States
Vamorolone 6.0 MG/KG/DAY
   ReveraGen BioPharma, Inc.
      2016   Phase 2   NCT02760264   Australia;Canada;Israel;Sweden;United Kingdom;United States
VBP15
   ReveraGen BioPharma, Inc
      2019   Phase 2   EUCTR2017-002704-27-GR   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom
   ReveraGen BioPharma, Inc.
      2019   Phase 2   EUCTR2017-002704-27-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002704-27-ES   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002704-27-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2017-002704-27-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002704-27-SE   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002704-27-GB   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004462-26-GB   Australia;Canada;Israel;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004263-38-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004262-26-GB   Australia;Canada;Israel;Sweden;United Kingdom;United States
   Santhera Pharmaceuticals (Schweiz) AG
      -   Phase 2   EUCTR2025-000201-16-Outside-EU/EEA   Canada
Ventilatory/ respiratory and other support assessment
   Hospital Universitari Vall d'Hebron Research Institute
      2021   -   NCT06924125   Spain
Vesleteplirsen
   SAREPTA THERAPEUTICS, INC.
      2022   Phase 2   EUCTR2019-000601-77-IT   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
   Sarepta Therapeutics, Inc.
      2021   Phase 2   EUCTR2019-000601-77-DE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000601-77-NL   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   NCT04004065   Belgium;Canada;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000601-77-BE   Belgium;Canada;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2020-004803-15-Outside-EU/EEA   Canada;United States
Viltepso
   NS Pharma, Inc.
      -   Phase 3   EUCTR2021-000122-10-CZ   Australia;Canada;Chile;China;Czech Republic;Czechia;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Viltolarsen
   NS Pharma, Inc
      2021   Phase 3   EUCTR2021-000122-10-IT   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003653-30-IT   China;Italy;Russian Federation;Spain;Turkey;United States
      2020   Phase 3   EUCTR2019-002076-13-IT   Australia;Belgium;Brazil;Canada;Chile;France;Greece;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   NS Pharma, Inc.
      2022   Phase 3   EUCTR2021-000122-10-NO   Australia;Canada;Chile;China;Czech Republic;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 2   NCT04956289   China;Italy;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   NCT04768062   Australia;Canada;Chile;China;Czechia;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Turkey;United Kingdom
      2021   Phase 4   NCT04687020   Canada;United States
      2021   Phase 3   EUCTR2021-000122-10-NL   Australia;Canada;Chile;China;Czech Republic;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000122-10-GR   Australia;Canada;Chile;China;Czech Republic;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000122-10-ES   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003653-30-ES   China;Italy;Russian Federation;Spain;Turkey;United States
      2021   Phase 3   EUCTR2019-002076-13-NO   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   NCT04060199   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002076-13-NL   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002076-13-GR   Australia;Canada;Chile;China;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002076-13-GB   Australia;Belgium;Brazil;Canada;Chile;France;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-002076-13-ES   Australia;Belgium;Brazil;Canada;Chile;France;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2008   -   NCT04337112   -
      -   Phase 3   EUCTR2021-000122-10-CZ   Australia;Canada;Chile;China;Czech Republic;Czechia;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2019-002076-13-SE   Australia;Belgium;Brazil;Canada;Chile;France;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Nippon Shinyaku Co., Ltd.
      2020   Phase 3   JPRN-jRCT2080224893   Asia except Japan;Europe;Japan;North America;Oceania;South America
VIT C VIT E ZN SE
   University Hospital, Montpellier
      2010   -   NCT01596803   France
VX-670
   Vertex Pharmaceuticals Incorporated
      2025   Phase 2   NCT06926621   -
      2024   Phase 1/Phase 2   NCT06185764   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
Vyondys 53
   Kevin Flanigan
      2020   Phase 2   NCT04179409   United States
   Rare Disease Research, LLC
      2020   Phase 4   NCT04708314   United States
Withings blood pressure monitor
   Centre for Human Drug Research, Netherlands
      2019   -   NCT04999735   Netherlands
Withings body+ scale
   Centre for Human Drug Research, Netherlands
      2019   -   NCT04999735   Netherlands
Withings steel HR
   Centre for Human Drug Research, Netherlands
      2019   -   NCT04999735   Netherlands
WVE-210201
   WAVE LIFE SCIENCES USA INC
      2018   Phase 1   EUCTR2017-002686-21-IT   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States
   Wave Life Sciences Ltd.
      2019   Phase 2/Phase 3   NCT03907072   Belgium;Canada;Czechia;France;Italy;Sweden;United Kingdom;United States
      2019   Phase 1   EUCTR2018-000975-34-NL   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States
      2018   Phase 1   NCT03508947   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States
      2018   Phase 1   EUCTR2018-000975-34-GB   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States
      2018   Phase 1   EUCTR2018-000975-34-BE   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States
      2018   Phase 1   EUCTR2017-002686-21-NL   Belgium;Czech Republic;Denmark;France;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 1   EUCTR2017-002686-21-GB   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States
      2018   Phase 1   EUCTR2017-002686-21-BE   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States
      -   Phase 1   EUCTR2018-000975-34-FR   Belgium;Canada;France;Italy;Netherlands;United Kingdom;United States
      -   Phase 1   EUCTR2017-002686-21-FR   Belgium;Czech Republic;Denmark;France;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
   Wave Life Sciences UK Limited
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-SE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-IT   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004009-22-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2018-004009-22-PL   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2018-004009-22-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2018-004009-22-FR   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2018-004009-22-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States
WVE-N531
   Wave Life Sciences Ltd.
      2021   Phase 1/Phase 2   NCT04906460   Canada;Jordan;United Kingdom
Xeomin
   Rigshospitalet
      2014   Phase 2   EUCTR2014-002210-23-DK   Denmark